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In the last decades, biomedicine opened its doors to stimuli-responsive 
biomaterials, with applications ranging from tissue engineering to drug 
delivery systems. Among them, polymers are by far the most investigated, 
thanks to their biocompatibility and their vast range of properties, tunable 
to match their end-use.  
Protein-based thermoresponsive materials are increasingly being studied, 
especially for drug delivery applications, where dedicated chemistries for 
on-demand capture and release of biomolecules at the solid-liquid interface 
are essential. This is an important requirement for the synthesis of 
switchable surfaces used in analytical devices and for the assembly of novel 
smart materials with complex architectures and functions.  
 
Here the design, synthesis and characterisation of novel peptide tags for 
reversible protein capture and thermoresponsive release from a solid 
surface are reported. The peptide sequences were inspired by the self-
assembling protein machinery dedicated to vesicle fusion in eukaryotes, 
known as the SNARE proteins.  
The three proteins involved, named SNAP25, syntaxin and VAMP, all 
present a highly preserved strand (SNARE motif) that allows them to 
assemble in a tight coiled-coil structure upon interaction, called SNARE 
II 
 
complex. This four α-helix bundle has remarkable chemical and thermal 
stability, withstanding temperatures up to 80°C and changes of pH.  
 
The structural features of the native ternary protein complex were 
engineered to yield a binary self-assembling polypeptide system. The first 
element of the binary system is a universal protein substrate immobilised 
on a solid surface. This protein mimics the neuronal SNAP25, which is 
involved in the docking and fusion of synaptic vesicles to the synaptic 
membrane.  The second element is a protein fusion of syntaxin and VAMP, 
acting as a polypeptide tag; it includes SNARE motifs from both syntaxin 
and VAMP, capable of self-assembly in a coiled-coil structure when coupled 
with SNAP25, even when immobilised on a surface. This interaction is 
strong but fully-reversible; therefore, this polypeptide tag can be 
recombinantly fused to a protein of interest to allow spontaneous assembly 
and stimuli-sensitive release from the surface upon heating at a 
predetermined temperature.  
Two VAMP-syntaxin protein fusions were produced, with different VAMP 
lengths: in the first, VAMP’s SNARE motif spans for 54 amino acids, 
matching syntaxin’s length. In the second, VAMP has been reduced to 25 
amino acids, truncated before the residue involved in the ionic layer, which 
helps stabilise the coiled-coil structure of the SNARE complex. The protein 
fusion with the shortened VAMP has been designed to weaken the SNARE 
complex thermal stability and test its disassembly temperature. 
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The recombinant proteins described above were characterised with 
pulldown assays and circular dichroism spectroscopy, testing their ability 
to form a stable SNARE complex. Two VAMP-syntaxin thermoresponsive 
tags are described: results show that the first one, with the 54-amino acid 
VAMP, presents remarkable thermal stability with Tm of the order of 80°C. 
The second tag, with the truncated VAMP, disassembles at a substantially 
lower temperature of about 45°C. The latter is a promising candidate for 
remote-controlled localised delivery of therapeutic proteins: the 
physiologically tolerable local increase of temperature in the 40-45°C 
range, also known as hyperthermia, can be achieved using magnetic fields, 
infra-red light or focused ultrasound. Notably, these two novel polypeptides 
provide an example for the engineering of future functional proteins with 
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1.1 Biomaterials for pharmaceutical applications 
 
 
Biomaterials are materials applied in biomedicine that have been 
engineered to safely interact with organisms, regulating therapeutic and 
diagnostic procedures (1,2). They can be of both organic and inorganic 
origin: ceramics, metals and polymers are the three main classes of 
biomaterials that are currently employed in medicine. Many of them can 
replace tissues, mimicking their biological, mechanical and chemical 
properties (1). Their compatibility with living systems makes them suitable 
to be used in implants, medical devices, as well as being used for 
pharmaceutical applications, for example, drug delivery. Bioactive glasses 
are commonly used as bone substitutes (3); stainless steel has been 
routinely utilised for dental implants, as well as bone replacements (once 
coated with calcium phosphate or other organic substances). Biomaterials 
require different properties (biodegradability, strength, durability, 
elasticity) that, especially for synthetic polymers, can be tuned to match 
the end-use. Some examples of polymer biomaterials are colloids, hydrogels 
and biofilms (4,5). 
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Polymers have an undoubted advantage in being flexible, making them the 
most utilised material in biomedical applications, from orthopaedics to 
drug delivery systems. They are relatively easy to produce, with a broad 
range of chemical and physical properties. Polymers can be synthetic or 
organic macromolecules, both entailing units covalently linked together. 
Most of their features can be tuned (molecular weight, composition, surface 
charges) to fit the desired scope. External stimuli can also be applied to 
trigger changes in some polymers, which is extensively being studied for 
biomedical applications, mainly to use them as drug delivery systems (6,7). 
 
Proteins were used as drugs for decades. One of the earliest examples is 
insulin, discovered at the University of Toronto in 1921 (8); Macleod and 
Banting won the Physiology Nobel Prize in 1923 for their breakthrough. 
Monoclonal antibodies are another excellent example of proteins used in a 
medical context (9); using “phage display”, Winter directed the evolution of 
antibodies, which led to the development of new pharmaceuticals, notably 
against autoimmune diseases (as rheumatoid arthritis). He began his work 
in the late ’80s and received the Chemistry Nobel Prize thirty years later, 
in 2018, for his contribution to engineer therapeutic proteins.  
Proteins have been increasingly studied for their pharmaceutical 
applications since the introduction of recombinant DNA technology.  
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This new know-how has the potential to turn many proteins into a 
medicinal drug, even if proteins are usually less stable than other 
pharmaceutical compounds and tend to biodegrade quickly in the 
bloodstream. Their compatibility with living organisms is a strength: a 
native (or slightly modified) protein can be highly specific without causing 
any harm or adverse reaction in an organism.  
 
Cancer therapy extensively uses protein nanoscale carriers and drugs, 
including multi-specific antibodies (mostly monoclonal antibodies) and 
fusion proteins; moreover, numerous immunotoxins against lymphoma are 
currently in clinical trials (10). The development of new cytotoxic drugs 
capable of reaching a specific target is crucial to increase drug 
concentrations in tumoural tissues and avoid dangerous side effects. 
Further modifications of cytotoxic proteins can lead to self-assembly and 
self-activation. Proteins can be associated with conventional drugs as a 
targeting agent (e.g. antibodies), or act as drug themselves. Olaratumab 
(monoclonal antibody) against sarcomas of the soft tissues, PEGylated 
Interferon against melanomas, Etanercept (trade name of a complex fusion 
protein) against lymphomas are only a few examples of protein drugs 
already employed for cancer therapy (see Figure 1.1).  
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Figure 1.1 Simplified scheme of anti-cancer drugs and their features. A) The 
standard chemotherapy approach is the use of chemicals (in red) that present cytotoxicity 
to both tumour and healthy cells. Their small molecular size (<5 nm, permitting renal 
clearance) and absence of target-specificity result in a distribution in the whole body. 
Linking such chemicals to nanoscale carriers and/or functionalising them with targeting 
agents can reduce their renal clearance and increase the drug concentration locally. B) 
Various roles of proteins for cancer therapy formulations. Abbreviations: EPR = Enhanced 
Permeability and Retention; PEGylation = linkage to polyethylene glycol. Image from 
Serna et al. (10).  
 
Despite an increase in the use of proteins in pharmaceutical science, the 
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1.1.1 Stimuli-responsive materials 
 
Scientists are developing both synthetic and modified biological materials 
that can sharply and reversibly change their conformation or phase in 
response to a stimulus. Stimuli can be either endogenous (changes in pH, 
enzyme concentration or redox gradients) or exogenous (magnetic field, 
ultrasound intensity, light or electric pulses, variations in temperature) 
(11). In biomedicine, these ‘smart’-polymers give life to, among others, 
biomimetic actuators, immobilised biocatalysts, drug delivery systems, cell 
culture surfaces, diagnostic and thermoresponsive surfaces (6,12). 
 
Polymers behaving like linear chains in solution can be triggered to fold 
and unfold or assist other proteins in avoiding possible aggregation (13,14). 
Polymers can also form gels through a network of cross-linked monomers: 
changes in their structure (like shrinking and stretching) can modify their 
pores’ size, releasing or retaining useful molecules. 
Bioactive molecules such as nucleic acids, small organic molecules, and 
peptides were combined with stimuli-responsive materials (12). They range 
from the micro- to the nano-scale, with infinite possibilities of combinations 
between stimuli, carrier and carried polymers (15) (see Figure 1.2). 
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Figure 1.2 Schematic of “Magic Cube” for stimuli-responsive materials. 
Combination of a variety of triggering mechanisms and carrier formulations for the 
delivery of a broad spectrum of functional proteins. Figure partially adapted from Lu et 
al. (15).  
 
Some thermoresponsive systems are capable of self-regulating their 
release rate thanks to a feedback mechanism. They can act directly inside 
the body and change their structure without any external triggering 
system (11,14,16). One excellent example are self-regulated insulin release 
systems (17,18,19); they make use of glucose-sensitive materials in the form 
of matrices and gels, releasing insulin in response to a change in glucose 
concentration. 
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‘Smart’ polymers face many challenges before their clinical approval, 
mainly due to their potential cytotoxicity. Drug delivery systems carrying 
peptides and nucleic acids, which primarily act within the cells, encounter 
the most difficulties (12).  
 
 
1.1.2 Thermoresponsive materials 
 
Amongst the stimuli-responsive materials, thermoresponsive polymers can 
serve numerous purposes (20). They are of particular interest in 
biomedicine to trigger novel drug delivery systems, as local changes of 
temperatures are technologically achievable using a wide range of 
methods. Once the smart polymers are inside the body, the temperature 
can be modulated either internally or externally (14), expanding their 
applicability in the field. The use of magnetic fields (21,16) and near-infrared 
lasers (22,23) is widespread in the biomedical field to activate 
thermoresponsive delivery systems. Focused ultrasounds is another 
external tool to induce changes in thermoresponsive polymers, where this 
stimulus triggers the rapid release of a drug and increases the temperature 
to facilitate diffusion (16,24). 
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Moreover, some cancers generate a slight increase in body temperature (1-
2°C) (25), while fever is a common reaction to inflammation. This 
temperature rise could help the activation of smart polymers in loco; 
however, these changes are not controllable, while temperature as an 
external stimulus can be modulated and employed locally (15,26,27).  
 
In order to deliver their payload in response to an increase in the 
temperature, thermoresponsive materials used in drug delivery need to 
change their structure rapidly. Their non- linear relationship with their 
triggering stimulus is of fundamental importance for their drug-release 
task, as they necessarily need to work as a binary switch with a controlled 
threshold (5,28,29).  
 
Hydrogels are found amongst the thermoresponsive materials and were 
extensively studied in the last few decades (30). They are simple polymer 
solutions at room temperature, acquiring a gel-form in physiological 
conditions, without any external-induced temperature modulation. Their 
high water content allows for swelling once injected into the body, releasing 
the moieties shielded between their cross-linked molecules (31,32). 
 
One of the main obstacles in the design of protein-based materials is how 
to increase their half-life. As an example, studies showed that the addition 
of polyethylene glycol (PEG) drastically improves smart polymers’ half-life 
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during circulation in the body, increasing the effectiveness of their 
deliverable payload (33,34,35). Small bioactive molecules such as PEGs 
improve aqueous solubility, extend plasma half-life and reduce renal 
clearance; they help to perform active intracellular delivery, and they show 
potential for targeted delivery. PEGylation (the addition of PEG on a 
polymer) was also performed on thermoresponsive drug delivery systems, 
showing increased stability and half-life (36). 
 
 
1.1.3 Protein-based thermoresponsive materials 
 
Biomaterials include different substances with a variety of properties, each 
suitable for a specific function. Among them, protein-based materials are 
by far the most adaptable to different purposes. Excellent examples of such 
materials are present in nature: spider webs are known for their 
remarkable strength, comparable to steel, and their extension properties 
(37). The human body has numerous polymers with unique characteristics, 
from collagen’s mechanical strength to elastin’s flexibility (38).  
 
Elastin is an insoluble protein, highly cross-linked, responsible for the 
structural integrity and elasticity of tissues and organs, from lungs to blood 
vessels. It is one of the critical components of the extracellular matrix and 
elastic fibres. Elastin’s properties gained the attention of many 
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researchers: elastin, in fact, is capable of self-assembly and rearranging its 
structure depending on the temperature; these properties are shared with 
tropoelastin, its precursor protein. Above the so-called Transition 
Temperature (Tt), elastin and tropoelastin rearrange in a more ordinated 
phase; this reversible event is called “inverse phase transition” (39,40). 
Elastin’s properties were ideal for the development of new protein-based 
materials, that were called elastin-like polymers (ELPs): ELPs are 
artificial derivatives of tropoelastin’s hydrophobic domains.   
 
The first ELPs were synthesised by Urry and his research group (40), where 
they extensively studied their properties in solution as well as their 
biomedical applications. Elastin-like polymers are soluble in solution; 
when heated to the transition temperature, they aggregate, becoming 
insoluble. This process is reversible, with a loss of water by the hydrophobic 
domains that can be reabsorbed once the temperature decreases below the 
critical threshold. ELPs are therefore considered a thermosensitive 
polymer: its conformational change directly depends on the temperature. 
 
Elastin-like polymers represent an excellent example of versatile 
thermoresponsive polymer; applications in biomedicine vary from tissue 
engineering (41), surface biofunctionalisations (42) to drug delivery systems 
(43,44,45). Some ELPs were developed to be soluble at body temperature and 
rapidly aggregate with a moderate increase of temperature (to 40-42°C). 
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The exploit of ELPs’ thermoresponsiveness to mild hyperthermia 
permitted targeting of solid tumours and increased drug uptake in loco 
(43,46). Elastin-like polymers were often associated with chemotherapeutics 
as doxorubicin, with promising results also in association with 
nanoparticles (47,48).  
 
Protein-based materials are increasingly being studied for their 
biocompatibility and tunable properties (49). In the last decade, numerous 
studies were conducted on protein-based thermoresponsive materials, 
often coupled with metal nanoparticles as a starting template, creating a 
vast range of versatile nanostructures (15,28,50,51). 
 
 
1.2 SNARE proteins 
 
The eukaryotic cell contains numerous organelles, each one with a 
dedicated function. These different compartments are maintained in 
equilibrium by rigid mechanisms. Homeostasis conducts this regulatory 
work on the material exchanged among the organelles, and what goes in 
and out of the cell. Vesicular transport is one of the selective exchange 
methods used by eukaryotes. Secretory vesicles are formed on the surface 
of an organelle, and they consequentially fuse with their target membrane 
(of another organelle). Coat proteins regulate the formation of the vesicle 
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from an organelle or a cell surface. At the same time, the fusion on the 
target membrane is controlled by a family of proteins, known as SNAREs 
(Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptors) 
(52,53,54). They are distributed both on the vesicle and the acceptor 
membrane: the fusion is possible thanks to their interaction (54). 
 
The SNAREs were initially identified in yeast when studying its secretory 
pathway (55), then proved to be present in all eukaryotic cells (56,57). The 
evolutionary conservation of the SNARE complexes among eukaryotes is 
indicated by the high similarity between yeast, endosomal and neuronal 
SNARE complexes (58,59,60). SNAREs can interact with their corresponding 
SNARE partners bringing membranes close together; therefore, SNAREs 
are to be considered “the engine of the membrane fusion” (61) (Figure 1.3). 
 
Three proteins participate in the formation of the SNARE complex: a 
Vesicle-Associated Membrane Protein (shortened as VAMP), syntaxin, and 
SNAP25, a 25kDa protein (55). Rothman and colleagues classified these 
proteins into two groups, vesicle (v-SNAREs) or target SNAREs (t-
SNAREs), based on their localisation (55,58). VAMP is a v-SNAREs, as it is 
located on the vesicle’s membrane; SNAP25 and syntaxin are t-SNAREs, 
as they are part of the target membrane (see Figure 1.3). 
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Figure 1.3 Model of two SNARE complexes during vesicle docking. The proteins 
that form the SNARE complex are represented in different colours: VAMP in blue, 
syntaxin in red, both with a yellow transmembrane domain; in green, SNAP25. Their 
interaction brings membranes close together, leading to membrane fusion. Figure adapted 
from Brunger et al. (62). 
 
SNAREs guide membrane fusion in most of the endo- and exocytotic 
pathways, including the release of neurotransmitters: these proteins are 
responsible for the docking of synaptic vesicles with the presynaptic 





All SNARE proteins are characterised by the presence of a SNARE motif: 
this is a ~60 amino acid strand organised in heptad repeats, allowing the 
formation of a coiled-coil structure arrangement with other SNARE motifs  
(63,64). In a SNARE motif, hydrophobic amino acids are overrepresented in 
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positions 1 and 4 (residues “A” and “D” in Figure 1.4). As a consequence of 
this pattern, the hydrophobic amino acids on different α-helices face each 
other within the core of the coiled-coil structure and the α-helices “zip” 
together from the N- to the C- terminal via the formation of hydrophobic 
layers. A central ionic layer helps with the overall stability of the core 




Figure 1.4 A downward cross-sectional view of the α-helical heptad repeats for 
a heterodimer forming a coiled-coil structure. Coiled-coil structures are made of 
aligned motifs with multiple heptad repeats (seven residues); in SNARE proteins, such 
strands are called SNARE motifs and are responsible for the formation of the SNARE 
complex. The scheme shows two α-helices with their axes orthogonal to the paper plane, 
and highlights the interactions between their heptad repeats: the seven residues are 
labelled with letters from “A” to “G”. Hydrophobic residues “A” and “D”, in orange, are 
involved in the formation of the hydrophobic core; charged residues “E” and “G” stabilise 
the overall structure forming salt bridges (positively charged = blue, negatively charged 
= green). Residues “B”, “C” and “F” are usually charged or polar. The SNARE complex is 
a tetrameric α-helix bundle, and the four α-helices behave as the heterodimer showed 
here, with the formation of the hydrophobic core thanks to hydrophobic residues of all four 
helices. SNAREs are characterised by a central ionic layer: the heptad repeats involved in 
its formation do not have hydrophobic residues in position “A” and “D”, but rather a 
glutamine or arginine residue, depending on the protein involved.  
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Syntaxin consists of three main domains: an N-terminal domain (here 
called NTD), a SNARE motif and a C-terminal transmembrane domain 
(TM) (see Figure 1.5 A). The transmembrane domain provides anchorage 
to the surface of the presynaptic plasma membrane, while the NTD is 
responsible for switching between an open and closed conformation (65). 
The conformational change of the N-terminal domain allows or prevents 
the interaction with other SNARE domains and has a regulatory function. 
 
VAMP has a short N-terminal region, the SNARE motif and a C-terminal 
transmembrane domain (TM) (Figure 1.5 A).  
 
SNAP25 has two SNARE motifs, located at the N- and C-terminal of the 
protein, which may work as independent domains (see Figure 1.5 A). It has 
no transmembrane region, as it is linked to the post-synaptic membrane 
through lipid anchors. Four cysteine residues present on the strand 
between the two SNARE motifs of SNAP25 covalently bind four palmitic 
acid residues on the surface of the membrane through S-palmitoylation. 
 
Syntaxin and VAMP contain one SNARE motif, while SNAP25 contains 
two (Figure 1.5 A). All the isolated SNARE motifs are largely unstructured 
(66,67,68,69); upon interaction, they fold tightly together, forming the SNARE 
complex (Figure 1.5 B).  
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VAMP and syntaxin present transmembrane regions as part of the 
synaptic vesicle and presynaptic membrane, respectively (Figure 1.5 C). 
 
Since the transmembrane and other accessory domains are not required 
for the assembly of the SNARE complex, in a significant proportion of the 
literature studying SNARE complex’s structure, the experiments were 
carried out with truncated recombinant SNAREs (62). These recombinant 
proteins can form a vast range of α-helical bundles structures, with 
different compositions and configurations (67,70).  
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Figure 1.5 The neuronal SNARE complex. (A) Primary structure diagram for SNAP-
25 (green), syntaxin (red), and VAMP (blue). SNARE motifs of each protein are 
represented by cylinders. Syntaxin and VAMP have a transmembrane domain (TM) at 
their C-terminal; syntaxin has an additional domain on its N-terminal (NTD). The two 
helices of SNAP25 are named H1 and H2. (B). X-ray crystal structure of the core of the 
Rattus norvegicus neuronal SNARE complex, formed by the SNARE motifs only (PDB ID 
1SFC). The alignment is parallel, so all the α-helices are oriented N- to C- terminal. 
(C) The SNARE complex during neuronal vesicle docking. The proteins that form the 
SNARE complex are represented in different colours as in (A). Figure adapted from 
Brunger et al. (62). 
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1.2.2 SNARE complex formation 
 
As mentioned above, all the SNAREs have one or two SNARE motif 
domains, which are very conserved among eukaryotes. The SNARE motif 
is the domain required to form the SNARE complex (see Figure 1.5 B); the 
four motifs together form an elongated four α-helix bundles with a parallel 
coiled-coil structure (59). The SNARE complex formation starts from the N-
terminal and proceeds towards the C-terminal direction (71).  
 
The interactions between side chains of the four α-helices form the core of 
the bundles: 16 layers, mainly hydrophobic, with a central ionic layer 
involving three glutamine (Q) and one arginine (R) residues provided by 
the four α-helices (Figure 1.6). Other than the t- and v-SNARE 
classification, these proteins can be categorised based on the amino acid at 
the ionic layer, resulting in the R- and Q-SNAREs nomenclature (72). 
The ionic layer, also known as ‘0’ layer, is protected from solvent thanks to 
the adjacent hydrophobic layers. It is highly conserved, although it can 
assume alternate conformations, as it has a role in the NSF-mediated 
disassembly of the SNARE complex (NSF stands for N-ethylmaleimide-
sensitive factor) (73).  
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Figure 1.6 Ionic layer of the synaptic fusion complex. The side chains involved in 
the ‘0’ layer of the SNARE complex are labelled with their respective protein and amino 
acid; they are displayed as balls and sticks. Backbones of the proteins are shown as 
ribbons. Figure adapted from Sutton et al. (59). 
 
 
1.2.3 SNARE complex properties 
 
The SNARE complex shows remarkable thermal and chemical stability. 
The interaction between SNARE proteins is not covalent; however, it is 
unusually stable and essentially irreversible. In fact, disassembly of the 
SNARE complex in physiological conditions happens enzymatically (NSF-
mediated) rather than being spontaneous. In vitro, the SNARE complex 
can withstand the denaturing conditions of Sodium Dodecyl Sulfate (SDS) 
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(74), even though this property is not present in all eukaryotes (70). 
Alternatively, the forced disassembly can occur upon heating over 90°C.  
Also, the SNARE complex exhibits resistance to cleavage by neurotoxins, 
whereas individual SNARE proteins are susceptible to them (74).  
 
The SNARE complex formation occurs thanks to the interaction between 
SNAP25, syntaxin and VAMP. Although largely unstructured when in 
solution, they acquire a strong α-helical conformation when together. The 
strength of the SNARE complex is needed to bind the two membranes 
together and form the fusion core; membranes are typically negatively 
charged, and therefore would not fuse spontaneously due to electrostatic 
repulsion. The amount of energy required to fuel the membrane fusion is 
provided by the assembly of the SNARE complex, which then allows the 
vesicle to release its content inside the target membrane. Studies on the 
formation of the SNARE complex showed a hierarchical interaction 
between the three proteins. SNAP25 and syntaxin’s closeness on the 
plasma membrane surface leads to the formation of a binary complex 
between the two proteins (68,75,76). Even when incubated together, there is 
a two-step assembly: the formation of a heterodimer of SNAP25-syntaxin 
happens first, then VAMP joins the other two proteins to form the ternary 
SNARE complex (see Figure 1.7). The formation of the SNAP-25-syntaxin 
binary complex significantly improves VAMP’s binding affinity more than 
the single proteins alone (74,75). 
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Figure 1.7 Simplified energy profile of the formation of the neuronal SNARE 
complex. The diagram shows that SNAP25 and syntaxin, both present on the plasma 
membrane, partially assemble into a heterodimer. The activation energy required for this 
step is lower (ΔGheterodimer), possibly due to other factors in vivo. The SNAP25-syntaxin 
heterodimer has a high affinity for VAMP; the proteins initially assemble at their N-
terminal, proceeding towards C-terminal. The total energy released by the formation of 
the entire complex is indicated with ΔGheterotrimer. Figure reworked from Wiederhold et al. 
(75). 
 
As seen in Figure 1.7, the formation of the four α-helix bundles releases 
energy, which is used to guide membrane fusion (61). The ternary complex 
has substantial stability compared to the heterodimer formed by SNAP25 
and syntaxin. 
Numerous researches were conducted on SNAREs, ranging from the 
investigation of complex formation (60,64) to detail studies on membrane 
fusion (77,78,79). The SNARE motifs play a vital role in the formation of the 
complex, and SNAREs were often engineered (through truncation, single 
amino acid modification) to study their behaviour (68,69,74,80). 
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1.3 Biochemical and biophysical characterisation 
of the SNARE complex 
 
Several methods have been applied to characterise SNAREs and their 
interactions. This section reports examples from the literature of the most 
common biochemical characterisation method, Sodium Dodecyl Sulfate 
PolyAcrylamide Gel Electrophoresis (SDS-PAGE), and the most common 
biophysical tool, Circular Dichroism. Examples where protein-protein 
interaction was analysed by pulldown assays are also reported. 
 
 
1.3.1 SDS-PAGE and GST-pulldown assay 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis, abbreviated as 
SDS-PAGE, is a well-known method to separate proteins based on their 
molecular weight. Samples, buffer and the gel contain sodium dodecyl 
sulfate; SDS is an anionic detergent that coats proteins with a uniform 
negative charge, masking the intrinsic protein charges. A reducing agent 
is also present within the loading buffer, usually β-mercapto ethanol or 
dithiothreitol (DTT), which, along with SDS, helps to disrupt the tertiary 
structure of proteins by breaking disulphide bonds. SDS coats proteins 
with a uniform negative charge; therefore, they run as linear molecules on 
the gel, with electrophoretic mobility depending only on their molecular 
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weight. The electric field attracts the SDS-coated proteins (negatively 
charged) towards the positive pole; larger proteins move slower than the 
small ones, caused by larger friction due to the viscosity of the gel. Protein 
standards, containing protein of known size, are run along with the protein 
samples to help identify their molecular weight. 
 
SDS-PAGE is used for the characterisation of SNARE proteins not only to 
assess their size but also to study the formation of the complex. Previous 
studies showed that the SNARE complex could withstand the denaturing 
conditions of the SDS-PAGE gel (60,74,81). By heating samples containing 
the SNARE complex, Hayashi et al. were able to analyse the single 
components and their stoichiometry; moreover, they demonstrated that the 
SNARE complex did not disassemble upon freezing and thawing, and it 
was stable even when exposed to temperatures up to 60°C for 5 minutes 
(74). SDS-PAGE has also been used as a readout to better understand the 
interactions and hierarchy of the SNARE complex formation, for example, 
through pulldown assays.  
Pulldown assays are generally used to characterise protein binding 
interactions. The protein of interest is expressed (or later modified) as a 
glutathione S-transferase (GST) fusion protein to be paired with 
glutathione (GSH) Sepharose beads. This technique can be used for both 
purifying a protein from a lysate and for studying its interactions with 
other proteins when incubated together. 
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GST-pulldown assays are useful to analyse protein-protein interactions 
between the SNARE proteins and are routinely used to study the formation 
of the SNARE complex and the proteins involved in it (60,82,83).  
As mentioned above, pulldowns can be analysed with SDS-PAGE; other 
methods such as fluorescence, can be utilised to assess protein-protein 
interaction when the protein carries a fluorescent probe (84).  
 
 
1.3.2 Circular Dichroism spectroscopy 
 
Circular dichroism spectroscopy is a technique in which the circular 
dichroism (CD) of molecules is measured over a specific range of 
wavelengths. CD spectroscopy can assess the changes in the secondary 
structure or conformation of macromolecules, particularly of proteins that 
have a secondary structure sensitive to its environment, temperature or 
pH (85,86,87). For thermo-sensitive proteins, it is possible to understand 
their conformational changes with the increase of the temperature (88).  
 
Circular dichroism was widely used as a rational way to analyse SNAREs 
(60,68,69,75), since their SNARE domains are unstructured when taken 
individually, acquiring an α-helical conformation only when placed 
together. When measured by CD spectroscopy, each one of the three main 
protein conformations generates a different type of curve in the spectrum. 
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A marked double minimum at 208 and 222 nm indicate α-helical structure, 
while a single minimum below 200 nm or around 217 nm reflects random-
coil and β-sheet, respectively (Figure 1.8).  
 
 
Figure 1.8 Typical far-UV SRCD spectra of proteins’ secondary structures. 
Differences between CD spectra of α-helix, β-sheet and random coil’s secondary structures. 
In blue, two minima peaks at 208 and 222 nm characterise α-helical structures; in red, a 
single minimum at 217 represents β-sheets, while in green the random coil conformation 
shows a minimum peak below 200nm. Figure from Wei et al. (89). 
 
SNAREs follow the typical circular dichroism α-helix pattern, with a double 
minimum at 208 and 222 nm, due to the interactions between SNAP25, 
syntaxin and VAMP’s SNARE motifs, the strands responsible for the 
formation of the four α-helix bundles. Figure 1.9 below shows that the α-
helical component of the SNARE complex reduces when diluting syntaxin’s 
concentration. SNARE motifs are unstructured when separated, acquiring 
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an α-helical conformation when in solution together with the formation of 
the four α-helix bundles (90). 
 
 
Figure 1.9 Far-UV SRCD spectra of SNARE complexes with different syntaxin 
concentration. SNAP25, syntaxin and VAMP were mixed together to allow the 
formation of the SNARE complex. SNAP25 and VAMP were maintained at the same 
concentration (81 μM), while the quantity of syntaxin was reduced (to 20.3 and 1.3 μM). 
The spectra show a progressive decrease in α-helicity upon dilution of syntaxin SNARE 
motif. CD spectra were recorded at three different protein concentrations (40 mM sodium 
phosphate buffer). The minima peaks correspond to 208 and 222 nm, characteristic 
features of the α-helical secondary structure. Figure from Margittai et al. (90). 
 
SNAP25, syntaxin and VAMP spontaneously assemble into a strong 
ternary complex, with a melting temperature (Tm) around 90°C. Circular 
dichroism spectroscopy is, therefore, a valid tool to analyse SNAREs’ 
secondary structure and its conformational changes concerning 
temperature variations (59,60,91). Melting curves can be obtained analysing 
the CD signal at 222nm at different set temperatures, allowing the 
analysis of SNARE’s behaviour upon heating to high temperatures. 
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1.4 Engineering of recombinant SNAREs  
 
SNAREs have been engineered for decades to study and understand their 
structural features. Most of them focused on the investigation of complex 
formation (60,64), with detailed studies on their role in membrane fusion 
(77,78,79) and binding regions (92). 
 
SNAREs were often engineered, for example, through truncation and 
single amino acid modification, to study their ability to form the SNARE 
complex (68,69,74,80). The SNARE motifs play a vital role in the formation of 
the four α-helix bundles, a structure with remarkable strength and thermal 
stability despite being non-covalently bound. SNAREs’ sequences were 
manipulated to test its ability to retain such properties. Evidence showed 
that the formation of the complex is still possible with one truncated helix; 
however, the strength of the complex is reduced (60,69,93).  
 
There are numerous studies on SNAREs as a bioconjugation system: 
Darios et al. used SNAP25, syntaxin and VAMP as versatile tags for a 
modular medicinal toxin, botulinum neurotoxin A. The research group 
linked two of the three SNARE proteins with the toxin’s domains that are 
inactive when taken individually: once reassembled driven by SNARE 
complex formation, the toxin became active and inhibited the release of 
neurotransmitters by targeted neuronal cells (84). SNARE tagging can, 
- 28 - 
 
therefore, be employed to target specific cells. Analogously, Ferrari et al. 
demonstrated that SNAREs could be exploited as protein tags for the 
irreversible combination of different protein domains (94). 
 
SNAREs can also be used to develop new immobilisations systems: Ferrari 
et al. demonstrated that it is possible to immobilise SNARE proteins on 
gold nanoparticles (81). They engineered the three SNARE proteins into two 
fusions, linking together VAMP and SNAP25, subsequently proving the 
ability of this SNARE fusion to bind its partner, syntaxin. A second set of 
SNARE fusions, with VAMP linked to syntaxin and SNAP25 acting as 
intended partner, was developed; thanks to a GST-fusion tag, they were 
both immobilised on different gold nanoparticles (GNPs). The SNARE 
fusion protein immobilised on the GNPs was capable of capturing the 
second component in solution, with no changes on their ability to form the 
SNARE complex. This study proves the possibility to engineer the ternary 
SNARE complex into a binary one, with the preservation of the ability to 
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1.5 Aim of the project 
 
The aim is to develop a binary protein complex, immobilised on a surface, 
able to assemble spontaneously and disassemble in response to a change of 
temperature. 
This work is built on previous evidence that SNAREs can be used for 
immobilisation on surfaces (81,82) (see Section 1.4), and its α-helices can be 
manipulated to modify its stability (93). Shortening of a SNARE domain 
was attempted before (93); however, it has never been exploited for 
thermoresponsive materials. 
 
The project’s three main aims: 
(i) modulation of the SNARE complex’s melting temperature by 
shortening of SNARE domains; 
(ii) re-arrangement of SNARE domains, including the shortened 
ones,  to engineer a thermoresponsive binary  SNARE complex;  
(iii) immobilisation and temperature-mediated release of the binary 
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1.5.1 Modulation of the SNARE complex’s thermal 
stability 
 
The SNARE proteins assemble in a parallel coiled-coil secondary structure 
with significant stability. The research focuses on Rattus norvegicus 
neuronal SNAREs, extensively studied in past literature (72,95,96). The 
design of new recombinant SNAREs focuses on the preservation of the 
SNARE motif, eliminating the transmembrane domains from the designed 
sequences.  
Numerous studies indicate that the SNARE complex can form even when 
one of the helices involved is truncated (60,68,80,94), yet it weakens its 
chemical stability. The ionic layer has a crucial role in the maintenance of 
the core complex stability so it is omitted in the design of the shortened α-
helix. Among the three proteins contributing to the SNARE complex, 
SNAP25 and syntaxin initially bind on the plasma membrane’s surface. 
VAMP is the last one to associate for the formation of the complex (68) and 
is hence chosen to be manipulated. Two versions of VAMP are designed: a 
54- and a 25-amino acid long protein, the latter truncated on the C-
terminus (see Figure 1.10). Previous studies showed that mutations at the 
N- and C-terminal side of SNARE proteins had different effects on the 
formation of the complex. Mutations at the N-terminal reduced the 
assembly of the complex, while C-terminal ones displayed no collateral 
effects (71).  




Figure 1.10 Truncation of the SNARE complex. The SNARE complex structure (PDB 
ID: 1SFC) is here represented with colour-coded sequences, highlighting the SNARE 
domains preserved in this project’s design. The SNARE complex has parallel alignment 
and, in this representation, the N-terminals of each polypeptide are all on the left. The N- 
and C-terminals of the SNARE domain polypeptides were chosen to span from the first 
coil (N-terminal) of the VAMP2 to the last coil (C-terminal) of Syntaxin 1, while preserving 
the same overall polypeptide length. This represents the ‘core’ SNARE complex, which 
presents typical features of a coiled-coil structure. SNARE motifs of SNAP25, syntaxin 1 
and VAMP2 are colour-coded, in green, red and blue respectively. Molecular weight and 
amino acid length are included in the description box. A second VAMP2, which differs in 
length and was named VAMP2-S (Short), spans for 25 amino acids, as its sequence was 
truncated before the ionic layer (highlighted in yellow). The shortened version of VAMP2 
was designed to weaken the complex’s thermal stability. On the top, the structure of the 
SNARE complex, with the three 54 amino acids long proteins highlighted in different 
colours. On the bottom, the newly designed version of the SNARE complex with the 
shortened version of VAMP2, truncated before the ionic layer (highlighted in yellow). 
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1.5.2 Engineering of binary SNARE complexes 
 
The SNARE proteins assemble in a supramolecular structure formed by 
four α-helices, with three proteins contributing to the formation of the 
bundle. However, this ternary system is not entirely suitable for 
biotechnological applications (81,84,94).  
The design of a binary SNARE complex would be favourable, as one 
element of the complex could be immobilised, whereas the second could be 
captured and released. The possibility to link together different SNARE 
fragments to form a recombinant protein allows the design of a variety of 
different combinations. Studies on the interactions between different 
SNARE proteins were examined; previous research showed that the 
binding affinity between VAMP and syntaxin is the weakest among the 
SNARE proteins (80). Therefore, the new SNARE fusion protein consists of 
syntaxin and VAMP linked together, whereas the second protein is a 
derivative of SNAP25 (Figure 1.11). 
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Figure 1.11 From ternary to binary: engineering of the SNARE complex. The 
three SNARE proteins are rearranged into SNARE fusions. Syntaxin and VAMP’s SNARE 
motifs, represented as cylinders, are fused together into two separate SNARE fusions 
(VS), differing on the VAMP’s length (L-Long and S-Short). The linker between the two 
motifs is the naturally occurring linker found between the two α-helices of SNAP25. HH 
is an analogue of SNAP25: its two SNARE motifs, represented as cylinders, are preserved 
along with the linker between the two of them. In all the fusion proteins, the four cysteine 
residues present in the linker, responsible of securing the protein to the membrane, are 
mutated to Alanine to avoid the formation of disulphide bonds. HH and VS partner to 
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1.5.3 Thermo-release of surface-immobilised proteins 
 
SNARE proteins have never been developed as thermoresponsive 
materials. The binary SNARE complex above addresses this as its 
properties are suitable for self-assembly and temperature-triggered 
disassembly. A SNAP25 derivative is immobilised on a solid-liquid 
interface by the addition of a GST domain (97) (see Figure 1.12). 
The ability of the immobilised SNAP25 to capture and release the VAMP-
syntaxin fusion in response to temperature increase is reported here and 
represents the first evidence of a new thermoresponsive released system 
based on engineered SNARE proteins.  
 
 
Figure 1.12 Schematic representation of the immobilisation and release of a 
binary SNARE complex from a surface. HH is expressed as a GST-fused protein and 
immobilised onto GSH Sepharose beads thanks to the high affinity between GSH and 
GST. GST-HH is capable to bind both kinds of VS (Long and Short), forming the SNARE 
complex. Upon mild heating (45°C), the shortened version can be disassembled from GST-
HH, while the longer VS, more stable, is still attached to the beads. 
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2. MATERIALS AND METHODS 
 
 
2.1 Protein design 
 
All the SNARE mimics used throughout this work were from Rattus 
norvegicus. The design focused on the neuronal SNARE motifs, omitting 
transmembrane and other accessory domains, with the exception of the 
linker in between the two SNARE domains of SNAP25 (see Table 2.1).  
 
 
Table 2.1 SNARE protein constructs. Single and fusion proteins list, their UniProtKB 
access numbers and relative amino acidic sequence. All the mentioned proteins are 
neuronal SNAREs from Rattus norvegicus. The HH construct is an alternative to SNAP25, 
formed by H1, H2 and l. H1 and H2 are the two α-helix sequences of SNAP25, while l is 
the unstructured linker located between them. The amino acid sequence of all proteins 
can be found in the Appendix (Table A.1).  
Construct Components Original name UniProtKB Amino acids
H1 Rat SNAP25B P60881 28-81
l Rat SNAP25B P60881 82-148
H2 Rat SNAP25B P60881 149-202
HH
Syntaxin 3 \ Rat Syntaxin 3 Q08849 200-253
VAMP2-S \ Rat VAMP2 P63045 31-55
VAMP2-L \ Rat VAMP2 P63045 31-84
Syntaxin 1 \ Rat Syntaxin 1A P32851 149-202
SNAP25 \ Rat SNAP25B P60881 1-206
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VAMP2 was designed in two forms, one long (L) and one short (S) to 
manipulate the SNARE complex’s thermal stability. VAMP2-L is 54 amino 
acids long and spans the entire SNARE motif. In VAMP2-S, however, the 
C-terminal was truncated before the ionic layer, resulting in a total length 
of 25 amino acids (see Table 2.2). The removal of the ionic layer was 
intended to avoid possible interference with the assembly of experimental 
conditions other than temperatures, such as change of pH and subsequent 
change of the overall charge. Also, improved assembly upon removal of the 
ionic layer of a shortened SNARE (syntaxin), in comparison to a shortened 
domain inclusive of the ionic layer, was reported before (94). The shortened 
VAMP2 was designed to study the impact of shortening on the formation 
and thermal stability of the SNARE complex. A cysteine residue was added 
at the C-terminal of both VAMP2-L and VAMP2-S to facilitate site-directed 
chemical cross-linking modifications, for example, fluorescent labelling 
(see below).  
 
 
Table 2.2 Sequences of VAMP2. Two different VAMP2 were designed, one spanning 
the entire SNARE motif (54 amino acids), the other truncated just before the ionic layer 
(25 amino acids). The sequences are represented from N- to C- terminal; the residue taking 
part in the ionic layer is highlighted in yellow. 
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Syntaxin 1 was also 54 amino acids long, which spans the entire SNARE 
motif and matches the length of VAMP2-L. Syntaxin 3 with same amino 
acid length was used in some experiment and constructs, due to its better 
expression rate in bacteria and engineering potential, compared to the 
most common partner of the neuronal SNARE complex syntaxin 1 (84). 
 
SNAP25’s expression plasmid was kindly provided by the MRC Laboratory 
of Molecular Biology (Cambridge, UK). The plasmid encoded the full-length 
protein but all the four cysteine residues in between the SNARE domains, 
which are involved in post-translational modifications in eukaryotes, were 
mutated into Alanine to avoid the unwanted formation of disulphide bonds. 
An alternative version of SNAP25 named HH was designed to have its 
SNARE motifs matching the amino acid length of VAMP2-L and the 
syntaxins (54 amino acids). The C-terminal and N-terminal SNARE 
domains of SNAP25 were truncated to 54 amino acids and fused using the 
same linker of SNAP25 above (the linker is named l in Table 2.1), with all 
the four cysteine residues mutated into Alanine. The fusion protein was 
named HH to underline the presence of the two SNAP25 α-helical (H) 
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2.1.1 Design of SNARE fusions 
 
Besides individual SNARE proteins, several hybrid fusion proteins, 
including SNARE domains from different SNAREs were designed; the 
purpose was to make a binary version of the naturally ternary SNARE 
complex. Sequences from Table 2.1 were combined, as indicated in Table 
2.3, but many SNARE fusions were either poorly expressed or difficult to 
elute due to low solubility (data not shown). The full synthesis and 
characterisation of binary complexes were carried over only for the most 
promising SNARE fusions (number 9, 10, and 11 in Table 2.3).  
 
 
Table 2.3 List of SNARE fusion designed and attempted. Eleven different SNARE 
fusion proteins were designed and expressed. SNARE motifs are represented as cylinders, 
while linkers as horizontal lines. The colour code helps distinguish the different motifs: 
red from syntaxins, green for SNAP25 (light for the first helix, dark for the second one), 
blue for VAMP2. The truncated VAMP2 is in light blue; the SNAP25 linker is in green, 
while the alternative one is represented in yellow. The protein fusions highlighted in grey 
were carried over and are described in detail in the following sections. 
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The new SNARE fusions were named VS-L (-L for Long) and VS-S (-S for 
short), concerning the length of the VAMP2 (54 or 25 amino acids long). 
The shortened version was designed to weaken the thermal stability of the 
overall complex. They were cloned, synthesised and characterised along 
with individual SNAREs as described in the following sections. An 
alternative version of VS-L, carrying the linker k and named VS-L2, was 
designed to exclude any interference of the linkers in the ability to form 
the SNARE complex. This artificial linker is a sequence of 48 glycine and 
serine residues, slightly smaller than the SNAP25 linker (67 amino acids 
long). Glycine and serine were chosen to give flexibility to the linker 
without carrying any charged residue. 
 
 
2.2 Cloning  
 
The amino acid sequences of target proteins were reverse translated (98) to 
DNA using a codon table for optimal expression in E. coli. A leading 
(TCTAGATGATCA) and an ending sequence (GGATCCTAGGAGCTC), 
respectively carrying the restriction sites of BclI and SacI, were added so 
that the DNA could be cut and inserted into a pGEX-KG GST gene fusion 
system (Addgene) via double enzymatic digestion, isolation of the fragment 
and consequent ligation. Synthetic DNA was purchased as synthetic genes 
cloned in pBSK II SK(-) vectors (Dundee Cell Products) encoding individual 
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SNARE domains or linkers designed as described in the previous section, 
except for VAMP2-S polypeptide, that was obtained by annealing of two 
ssDNA oligos with complementary sequence (IDT DNA Technologies).  
 
 
2.2.1 Subcloning of synthetic genes 
 
Purchased cloning vectors containing the DNA of interest were subcloned 
in expression vector pGEX-KG (Addgene). The constructs for SNARE 
fusions and HH, requiring more than one DNA sequence, were cloned 
iteratively, using a convenient modular approach developed for this project 
(see Section 2.2.3).   
 
 
2.2.2 Propagation of unmethylated plasmid DNA 
 
As BclI digestion is sensitive to DNA methylation, plasmids were 
propagated in methyltransferase-deficient E. coli competent cells (C2925I, 
New England BioLabs). 1 μl of the vector was incubated for 30’ in ice with 
30 μl of C2925I competent cells, followed by heat shock (42°C for 2’ then in 
ice for 4’) for DNA uptake. 300 μl of super optimal broth (SOB) medium 
pre-warmed at 37°C were used to grow the bacteria for 1 h at room 
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temperature under agitation (1000 rpm). After incubation, 10 μl and 100 
μl of the culture were spread onto two Luria-Bertani (LB) agar plates 
containing 100 μg/ml ampicillin to select only the transformed cells. The 
plates were incubated over-night at 37°C until colonies were big enough to 
be well visible. One colony was selected to grow in a 20ml sterile tube with 
5 ml of 2xTY (16 g/L tryptone, 10 g/L yeast extract, 5.0 g/L NaCl) medium 
containing 50 μg/ml ampicillin. The mini-culture was grown overnight at 
37°C to bring the population at saturation. Once grown, 2 ml of the culture 
were pipetted into 2ml Eppendorf tubes to harvest bacteria by 
centrifugation using a benchtop centrifuge at 3000 g. QIAprep Spin 
Miniprep Kit (QIAGEN) was used to extract the plasmids from each pellet, 
following the procedure indicated by the supplier. Once the column dried, 
the DNA was eluted with 50 μl of milli-Q water in a 1.5 ml Eppendorf tube. 
2 μl of purified plasmid DNA were used to measure DNA concentration and 
purity using a Nanodrop spectrophotometer (Thermo Fisher Scientific). 
 
 
2.2.3 Double digestion of origin and destination 
plasmids 
 
Un-methylated pBSK vector containing the insert of interest and pGEX-
KG expression plasmid (Addgene) were double digested for subsequent 
oriented annealing and ligation. The destination vector was digested at the 
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multiple cloning site using BamHI and SacI, while BclI and SacI were used 
for the origin vector, as these pairs result in matching sticky ends (Figure 
2.1). Specifically, BamHI and BclI digestions both produce a GATC 
overhang, but upon annealing and ligation of a BclI end onto the BamHI 
end from the destination vector, the original BamHI restriction site 5’-
GGATCC-3’ will become 5’-GGATCA-3’ and the vector will be protected 
from further BamHI digestion at this location. All the inserts used in this 
work have been provided with an adaptor at the 3’ end which carries a 
BamHI site just before the stop codon and the SacI restriction site. 
Therefore, the subcloning will produce a plasmid that can be still digested 
using the BamHI/SacI pair and serve as the destination vector of another 
BclI/BamHI insert that will be expressed at the C-terminal of the product 
of the first sequence.  
 
This modular approach was designed to iteratively clone different 
combinations of SNARE domains, starting from a limited number of 
building blocks (BB). For example, three iterations of the cloning using 
three different BBs designed with same adaptors would result in the 
tandem 5’-BB1-BB2-BB3-3’. The sequence at the adaptors at both ends and 
in between the BBs conveniently encodes for the amino acids glycine and 
serine, providing an uncharged, small and yet flexible linker between 
domains. 
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Figure 2.1 Outline of the modular cloning strategy.  (A) Enzymatic digestion 
generates sticky ends in both origin and destination plasmid (highlighted in yellow and 
green, respectively); the stars (*) represent Building Block 1 (BB1), the first DNA segment 
of interest. (B) The result of the ligation: BB1 was inserted in the pGEX-KG plasmid. A 
new BamHI site (turquoise), followed by a red stop codon,  allows a “reset” of the resultant 
plasmid. (C) The same plasmid becomes a new destination plasmid that can host an insert 
with the same design (highlighted in green the sticky ends generated by the new 
BamHI/SacI cut). (D) Thanks to this cloning strategy, BB 2 and 3 can be added to the 
plasmid. (E) GGATCA bases between Building Blocks codify for a Glycine and Serine 
residues. (F) The Building Blocks will be expressed as one protein, separated by GS 
residues. 
 
Double digestions were performed as follows. All the enzymes used were 
provided by New England BioLabs. 6 μl of the destination vector pGEX-KG 
were mixed with 7 μl of milli-Q water, 1.5 μl of 10x CutSmart Buffer and 
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0.25 μl of both BamHI_HF and SacI. 35 μl of un-methylated pBSK vector 
containing the insert were mixed with 4 μl of 10x CutSmart Buffer and 0.5 
μl of both BclI and SacI. The reactions were incubated at 37°C for 1 h; 
BClI/SacI double digestions were incubated for one extra hour at 50°C, as 
it is BclI’s optimum incubation temperature. All the reactions were then 
incubated for 10’ at 65°C to inactivate the enzymes and limit non-specific 
digestion products that may occur with extended incubations. pGEX-KG 
was stored for subsequent use in ligation reactions, whereas the DNA 
insert of interest was purified from the digested origin vector using the 
procedure described below.  
 
 
2.2.4 Purification of a double digested DNA insert 
 
To ensure a high yield of the purified insert for easy extraction from an 
agarose gel, the volume of the insert digestion above was set to 40 μl. First, 
5 μl of the digestion mixed with 1 μl of 6X DNA loading buffer was loaded 
in 1% Agarose gel containing 1X SYBR safe (Thermo Fisher Scientific), 
along with a sample of the corresponding uncut plasmid and 1Kb DNA 
ladder, to check for successful enzymatic digestion. The gel ran in tris-
borate-EDTA (TBE) buffer for 30’ at 100 V. Once the presence of the 
fragment was confirmed, the remaining 35 μl of the digestion were mixed 
with 7 μl of 6X loading buffer and loaded on the same gel along with a 100 
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bp DNA ladder under the same conditions as the last run. To isolate the 
DNA fragment, the gel was excised with a scalpel in a dark room on a UV 
transilluminator, and the part was placed in a 2 ml Eppendorf tube. The 
fragment was purified with a QIAquick Gel Extraction Kit following the 
procedure indicated by the supplier. The DNA insert was eluted in 50 μl of 




2.2.5 Synthesis of a DNA insert by annealing of ssDNA 
oligos 
 
As agarose gel purification of short DNA inserts and their subclonings 
present challenges, the small insert required to encode VAMP2-S was 
obtained from DNA oligos instead of using synthetic genes and the 
subcloning procedure described so far. The amino acid sequences of 
VAMP2-S was reverse translated to DNA as the genes described above. 
Also, a reverse complement was obtained, naming the two sequences 
Oligo1 and Oligo2, respectively. A leading (GATCA) and ending 
(GGATCCTAGGAGCT) sequences were added to Oligo1. Only a leading 
sequence (CCTAGGATCC) and a simple nucleotide T at the end were 
added to Oligo2. These were required for the cloning; moreover, they 
facilitated the insertion of another fragment following the modular 
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approach (see Section 2.2.3). The synthetic oligos service was provided by 
IDT DNA Technologies as standard desalted oligos shipped dried in tubes 
(0.05 micromoles). A 100 μM working stock solution of the oligos was 
prepared by mixing Oligo1 and Oligo2, along with 200 mM NaCl and milli-
Q water. The mixture was incubated at 95°C in a heat block for 10’ and left 
to cool down at room temperature for 2 h.  
As the design and the resulting sticky ends of the annealed oligos are fully 
compatible with the modular cloning strategy described above, the DNA 
insert was used in subsequent ligation in the same way as any other 





The ligation reactions between DNA fragments presenting oriented sticky 
ends were assembled using 16 μl of purified or annealed DNA insert, 2 μl 
of 10x T4 DNA Ligase buffer, 2 μl of digested pGEX-KG (or pGEX-KG 
containing previously subcloned building blocks) and 1 μl of T4 Ligase 
(New England Biolabs), in a total volume of 20 μl. The reaction took place 
at 37°C for 2 h. After this, the ligase was inactivated at 65°C for 20’.  
1 μl of the ligation reactions was used to transform 30 μl of competent cells. 
C2925I methyltransferase-deficient competent cells were utilised 
whenever additional cloning steps were required; alternatively, XL1 blue 
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competent cells (Agilent) were used when plasmids did not require any 
subsequent restriction using methylation-sensitive BclI. The cells and 
ligation product mixture were incubated for 30’ in ice, followed by a heat 
shock (42°C for 2’ then in ice for 4’). 300 μl of SOB medium pre-warmed at 
37°C were added to grow bacteria for 1 h at room temperature in agitation 
(1000 rpm). To select only cells with ligation products, 10 μl and 100 μl of 
the sample were spread on LB agar plates containing 100 μg/ml ampicillin. 
The two different concentrations were used due to the unknown 
transformation efficiency after ligation.  
The plates were incubated over-night at 37°C until colonies were big 
enough to be visible. Three or four colonies were collected, and each was 
grown in a 20 ml sterile tube with 5 ml of 2xTY containing 50 μg/ml 
ampicillin. The mini-cultures were grown overnight at 37°C, and 2 ml of 
saturated cultures were pipetted into 2 ml Eppendorf tubes to harvest 
bacteria by centrifugation on a benchtop centrifuge at 3000 g. QIAprep 
Spin Miniprep Kit (QIAGEN) was used to extract the plasmid, using the 
procedure indicated by the supplier. Once the column dried, the DNA was 
eluted with 50 μl of milli-Q water in a 1.5 ml Eppendorf tube. 2 μl of 
purified plasmid DNA was used to measure DNA concentration and purity 
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2.2.7 Verification of the cloning 
 
Samples of three to four purified plasmids per ligation were screened for 
the presence of the target DNA using double digestion. A 15 μl reaction 
was made up of 6μl of plasmid DNA, 7 μl of milli-Q water, 1.5 μl of 10x 
CutSmart Buffer and 0.25 μl of two selected enzymes between SacI, NarI, 
AvrII and EcoRV. The exact pair was selected depending on the target 
sequence, so one restriction site was within the expected insert and the 
other elsewhere in the expression vector. The double digestion reaction was 
incubated at 37°C for 1 h, then 10’ at 65°C to inactivate the enzymes. To 
check the digestion pattern, 5 μl of the reaction were mixed with 1 μl of 6X 
DNA loading buffer and loaded on 1% Agarose gel containing 1X SYBR safe 
(Thermo Fisher Scientific), along with a sample of undigested plasmid and 
1 Kb DNA ladder. The gel ran for 1h at 100 V.  
 
An example of such verification is shown in Figure 2.2, where the plasmid 
coding for VAMP2-L+linker is compared to the VAMP2-L alone. The 
digestion of these two plasmids with AvrII and EcoRV produces different 
fragments, visible on the gel. From their size, it is possible to assess which 
clones have been successfully ligated.  
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Figure 2.2 Example of successful insertion verification. On the left, the plasmid 
map of pGEX-KG_VAMP2-L and pGEX-KG_VAMP2-L+linker l. The arrows represent the 
inserts of interest; on the bottom one, the addition of linker l has been marked in black. 
The enzymes chosen for this specific digestion were AvrII and EcoRV, with sites indicated 
on the map; the sequence recognised by AvrII  (CCTAGG) can be found near the end of 
both inserts, as it is part of the ending sequence added during the first step of the cloning 
process (GGATCCTAGGAGCTC, see Section 2.2). In the central part of the image, the 
view of fragments originated from the restriction run on a 0.7% agarose gel, along with a 
1kb DNA ladder. A stands for VAMP2-L while B indicates VAMP2-L+linker l. The 
insertion of the linker adds 207 bp to the EcoRV-AvrII fragment; therefore, the difference 
between the two plasmids is easily identifiable on the gel run. On the right, the restriction 
fragments obtained in silico, following the colour scheme: blue for VAMP2-L and orange 
for VAMP2-L+linker l. Images reworked from results obtained with NEBCutter2.0 (New 
England Biolabs). 
 
The selected plasmids, whose digestion pattern suggested the presence of 
an insert, were delivered to Source Bioscience (Rochdale) and sequenced 
using the standard primer pGEX5 to confirm the sequence of the insert and 
conclusively select the successful clones (see Section B of the Appendix for 
DNA sequencing data).  
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2.3 Protein expression and purification 
 
All the recombinant proteins were expressed in BL21-gold (DE3) pLysS 
cells, which is a strain of E. coli suitable for low-temperature expression 
induced by isopropyl β-d-1-thiogalactopyranoside (IPTG).  
 
2.3.1 Transformation of competent cells 
 
30 μl of BL21-gold (DE3) pLysS cells (Agilent) were incubated for 30’ in ice 
with 1 μl of the expression vector containing the desired insert. The 
procedure used was similar to the one described for cloning. However, in 
addition to ampicillin used to select the plasmid containing the DNA insert, 
100 μg/ml chloramphenicol were also added to the LB plates and media, as 
the induction-control plasmid pLysS carried by this strain expresses a 
chloramphenicol resistance gene. Moreover, the volumes of the bacterial 
culture spread onto the plates were smaller compared to the 
transformations described for cloning, specifically 5 μl and 50 μl, due to the 
extremely high transformation efficiency and fast growth rate of these E. 
coli competent cells. 
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2.3.2 Low-temperature expression and purification of 
GST fusion proteins 
 
Selected individual colonies from the transformation plates were placed in 
50 ml falcon tubes with 5 ml of 2xTY (16 g/L tryptone, 10 g/L yeast extract, 
5.0 g/L NaCl) medium containing 50 μg/ml of ampicillin and 50 μg/ml of 
chloramphenicol. Falcon tubes were incubated overnight at 37°C; the 
resulting saturated cultures were poured into 500 ml of 2xTY medium 
within 2-litre flasks, containing 50 μg/ml of both ampicillin and 
chloramphenicol. The large volume of the flasks ensured adequate aeration 
during the 2 h 30’ incubation at 37°C in a shaker incubator (Innova S44i, 
Eppendorf). The incubation was stopped when the optical density (OD) at 
600 nm was between 0.5 and 0.7. This OD value corresponds to the optimal 
exponential phase of bacterial growth, as they have not yet reached the 
stationary phase, leaving them space to grow further without 
compromising their vitality.  
 
Protein expression was induced by adding 0.1 mM IPTG (Melford), and the 
flasks were incubated overnight at 18°C in agitation. The bacterial cultures 
containing the overexpressed protein were poured into 500 ml 
polycarbonate bottles and were spun at 3000 g for 20’ in a Beckman J25 
centrifuge equipped with a JLA-10.500 rotor to pellet the bacteria and 
remove the growth media. Pelleted bacteria were kept in ice, suspended in 
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10 ml of 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazine-ethane-sulfonic 
acid, ThermoFisher Scientific), 500 mM NaCl and 1 mM EDTA 
(ethylenediaminetetraacetic acid, Sigma-Aldrich). Once transferred into 50 
ml falcon tubes, 300 μl of complete protease inhibitor cocktail (Roche, from 
a 50X stock) were added, along with 10 μl of 1 mM DTT (dithiothreitol, 
Sigma-Aldrich). Cell walls were disrupted by temperature shock using fast-
freezing in liquid nitrogen for 10’, followed by thawing in the water at room 
temperature for 30’. 12 μl of 1M MgCl2 stock were added along with 400 μl 
of 1 mg/ml deoxyribonuclease I from bovine pancreas (Sigma-Aldrich) to 
reduce the viscosity of the lysate due to nucleic acids. The mixtures were 
left to rotate at room temperature for 10’. 1.5 ml of 0.1% v/v triton (TX-100) 
was added to achieve a final concentration of 2% and incubated for 20’ at 
4°C to disrupt cell membranes.  
 
Affinity purification was carried out using Glutathione Sepharose 4B resin 
(GE Healthcare). As all the proteins of interest were expressed as a C-
terminal fusion to a GST affinity tag from pGEX-KG derived expression 
plasmids, the glutathione (GSH)/GST interaction allowed their easy 
separation from other proteins in the bacterial lysate. 1 ml of GSH 
Sepharose beads was washed twice by centrifugation for 1’ at 1500 g within 
a 15 ml falcon tube and using a 20 mM HEPES, 100 mM NaCl, 0.1% v/v 
TX-100 and 1 mM EDTA Low Salt buffer. The lysate was pelleted at 10000 
g for 20’ at 4°C using a J25 centrifuge (Beckman) equipped with JA-25.50 
rotor. The pellet containing insoluble fraction was discharged, while the 
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soluble protein-rich supernatant was poured onto the GSH Sepharose 
beads and incubated in constant and slow rotation for 1 h 30’ at 4°C.  
 
The unbound fraction (flow-through) was removed by centrifugation using 
the same conditions used when washing the beads. The beads were washed 
twice using a 20 mM HEPES, 1 M NaCl, 1 mM EDTA and 0.1% v/v TX-100 
buffer with the same centrifuge settings. 15 μl of 1 mM DTT were added at 
each washing step to prevent the formation of unwanted disulphide bonds. 
Two extra washes were carried out in the same way with Low Salt buffer 
(see above), which was also used for final resuspension to a volume of 7 ml. 
Additional 15 μl of 1 mM DTT and 8ml of glycerol were added to the beads 
and mixed well before storage at -20°C. 1 μl of supernatant, 1 μl of flow-
through and 2 μl of washed beads were mixed with 10 μl of 1X loading 
buffer. Samples were heated at 100°C for 5’ and then loaded on an SDS 
PAGE gel (12% pre-cast polyacrylamide gel, Expedeon) along with a 
protein marker (Precision Plus, BioRad). The gel was run at 170 V for 1 h 
with 1X SDS RunBlue running buffer (Expedeon) and stained using 
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2.3.3 Protein elution 
 
Proteins were eluted from affinity GSH Sepharose beads using thrombin 
cleavage site (amino acid sequence LVPRGS) encoded in pGEX-KG and 
located between the GST tag gene and the multiple cloning site. The beads 
with the GST protein captured were washed twice with storage buffer (20 
mM HEPES, 100 mM NaCl, pH=7.4), the volume of the suspension was 
brought to 2 ml, and the beads were transferred in a 2 ml Eppendorf tube. 
100 μl of thrombin (Sigma-Aldrich) were added to the beads; the mixture 
was incubated for 1 h at room temperature under mild agitation.  
 
After incubation, the beads were loaded on a spin column with a filter cup 
(Thermo Fisher Scientific) and centrifuged at 3000 g on a benchtop 
centrifuge to separate GSH Sepharose beads from the eluate. 30 μl of 
Protease Inhibitor Cocktail (Roche) were added to the eluate to stop 
thrombin cleavage. The beads were then resuspended in 1.5 ml of storage 
buffer. 2 μl of the beads before and after cleavage and 1 μl of the eluate 
were prepared for SDS-PAGE by mixing with 10 μl of loading buffer. 
Samples were heated at 100°C for 5’ and load on the gel after cooling. The 
gel was run at 170 V for 1 h with 1X SDS RunBlue running buffer. 
InstantBlue stained gel was used to evaluate the efficacy of elution by 
thrombin cleavage. 
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Proteins for which the GST tag was retained (GST-HH and control GST), 
were eluted using excess glutathione in solution instead of proteolysis. The 
GSH Sepharose beads with the GST-protein immobilised on them were 
washed twice with storage buffer, and then incubated for 30’ at 4°C in 5 ml 
of GSH elution buffer (15 mM Glutathione H, 20 mM HEPES and 250 mM 
NaCl, pH=8.5).  
 
After incubation, the beads were spun, and the eluate was saved. 1 ml of 
extra GSH elution buffer was added again to the beads and incubated for 
15’ at 4°C to increase the yield of elution. The beads were spun again, and 
the second eluate was saved. 5 ml of storage buffer were used to resuspend 
the beads. 2 μl of first and second eluate and the resuspended GSH 
Sepharose beads were loaded onto an SDS-PAGE mixed with 10 μl of 
loading buffer. Samples were heated to 100°C for 5’ before loading. The gel 
was run at 170 V for 1 h with 1X SDS RunBlue running buffer and stained 
with InstantBlue to verify the elution. 
 
 
2.3.4 Fluorescent labelling 
 
Eluted proteins requiring incorporation of a fluorescent probe were labelled 
after elution using Cy5-maleimide (GE Healthcare), which reacts with free 
thiols at cysteine residues. A Vivaspin column (GE Healthcare) with a 
- 56 - 
 
molecular weight cut off of 3 kDa (VAMP2-S) or 10 kDa (all other proteins) 
was used to reduce the volume of the eluate down to ~600 μl.   
 
The proteins ( >50 μM concentration) were incubated with 4 μl of 0.5 M tris 
2-carboxyethyl phosphine (TCEP), a reducing agent, for 2 h at room 
temperature. 10 μl of maleimide-activated Cy5 (10 mg/ml in DMSO) were 
added and initially incubated for 30’ at room temperature. Incubation was 
prolonged at 4°C overnight to increase the yield of the reaction. Excess 
fluorophore was removed following subsequent purification by size 
exclusion chromatography (see below). SDS-PAGE of fluorescently-labelled 
proteins was analysed using Odyssey (LI-COR Imaging System). The gel 
was observed at the 700 nm channel, as Cy5 absorbance peak is at 649 nm.   
 
 
2.3.4 Fast Protein Liquid Chromatography 
 
A Vivaspin column (GE Healthcare) with a molecular weight cut off of 10 
kDa (3 kDa in the case of VAMP2-S) was used to reduce the volume of the 
eluate down to ~600 μl. The concentrated protein was separated by size 
exclusion chromatography using an ÄKTA Pure chromatography system 
(GE Healthcare) equipped with Superdex 75 10/300 GL column 
(alternatively, a Superdex 200 10/300 GL column).  
- 57 - 
 
The elution in storage buffer (20 mM HEPES, 100 mM NaCl) was collected 
in 1ml fractions, and those showing high absorbance at 280 nm were loaded 
onto an SDS-PAGE gel to confirm molecular weight. 9 μl of the samples 
were mixed with 3 μl of 4X loading buffer, heated to 100°C for 5’, and loaded 
with a protein marker (Precision Plus, BioRad). The gel was then run at 
170 V for 1 h with 1X SDS RunBlue running buffer and stained using 
InstantBlue.  
 
The fractions where the protein of interest was confirmed by molecular 
weight and the concentration was visibly high were combined, aliquoted 
and stored at -80°C.  
 
 
2.4 Protein characterisation 
 
The SNARE proteins and SNARE constructs characterisation is described 
below; it started with the determination of their concentration, followed by 
tests on their SNARE complex’s formation capabilities and thermal 
stability. In addition, their capture-and-release abilities were examined. 
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2.4.1 Protein concentration determination 
 
Protein determination was obtained by bicinchoninic acid (BCA) assay 
(Pierce, Thermo Fisher Scientific) and performed in triplicate for each 
protein against a standard curve obtained from Bovine Serum Albumin 
(BSA) standards (ThermoFisher). The assay was performed using the 
microplate procedure documented by the supplier, and absorbance of 
standards and unknown samples were read using an Infinite 200 Pro plate 
reader (TECAN).  
 
 
2.4.2 Synchrotron Radiation Circular Dichroism 
 
Synchrotron Radiation Circular Dichroism (SRCD) was used to assess the 
formation of the SNARE complex once the SNARE proteins were mixed. 
All the Circular Dichroism measurements were performed at the B23 
beamline for SRCD at Diamond Light Source (UK) (85). Each test contained 
2 µM protein solutions diluted in 5mM HEPES (pH 7.3) and 25 mM NaCl. 
Far-UV SRCD spectra, in the range of 180-260 nm, were recorded using a 
cylindrical cuvette with 0.2 mm optical path (Starna) in constant rotation.  
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Temperature scans were obtained using a custom Peltier device embedded 
into the cuvette holder at the B23 beamline. The temperature span chosen 
for the thermal unfolding assay was 25-95°C. The SRCD spectra were 
recorded at increasing temperatures with an interval of 2.5°C. The 
temperature was increased at the rate of 1°C per minute, followed by a 2 
minutes equilibration before collecting the spectrum.  
 
The thermal unfolding curves were plotted by selecting the data points at 
222 nm over the range of temperatures scanned (99). All SRCD spectra were 
processed using the software CDApps (100). 
 
 
2.4.3 Pull-down and controlled release 
 
Pull-down assays were performed to study protein-protein interactions 
(101). A traditional pull-down experiment was used to assess the ability of 
GSH Sepharose beads modified with GST-HH to capture VS-L and VS-S, 
forming the SNARE complex. A modified pull-down assay with washing 
steps at different temperatures was also developed to evaluate the 
responsive release of engineered SNAREs in a range of temperatures.  
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GSH Sepharose beads were incubated with 5µM of either GST-HH or GST 
(acting as a negative control) for 1 hour at constant agitation. Further 1-
hour incubation with 7.5 µM of VS was followed by thorough washing with 
20 mM HEPES pH7.3 and 100 mM NaCl. SDS-PAGE electrophoresis of 
beads after washing was carried out using 12% RunBlue SDS pre-cast 
protein gels (Expedeon), stained using InstantBlue (Expedeon) and imaged 
using ChemiDoc imaging system (Biorad). SDS-PAGE of beads could only 
provide a qualitative estimation of the protein amount retained. 
 
To easily detect the signal of the amount of protein immobilised on the GSH 
Sepharose beads after pull-down and monitor their controlled release at 
different temperatures, a 5 μM excess of either VS-L-Cy5 or VS-S-Cy5 were 
incubated with Sepharose-GST-HH beads, as for the pull-down mentioned 
above. After 1 h of incubation, the excess of VS was removed through two 
washes with a 20 mM HEPES pH7.3 and 100 mM NaCl (pH storage buffer 
followed by 1’ centrifugations at 7000 g. Nine fractions of the Sepharose-
GST-HH/VS complexes were incubated for 20 minutes at a set temperature 
(from 20°C to 80°) in a heat block. A set of Eppendorf tubes containing 2 ml 
of 20 mM HEPES and 100 mM NaCl buffer were incubated along with the 
samples. After a 30’’ centrifugation at 7000 g, the quick removal of the 
supernatant (which contained the unbound protein) was followed by a 
wash with the above-mentioned heated buffer at the same incubation 
temperature. The samples were then re-spun at 7000 g for 1’. The 
supernatant was removed again and the Sepharose-GST-HH/VS 
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complexes were resuspended in storage buffer at 20°C. The residual Cy5 
fluorescence in the fractions was measured with Infinite 200 Pro plate 
reader (TECAN), excitation and emission wavelength of 640 and 680 nm, 
respectively. This number represents the proportion of VS still bound to 
the surface at each tested temperature.  
 
Furthermore, the ability to capture and release VS has been tested with 
repeated cycles of heating and cooling at 20°C. The heating temperature 
varied according to the VS used: the Sepharose-GST-HH/VS-L-Cy5 system 
was heated up to 90°C, while VS-S-Cy5 reached a maximum temperature 
of 50°C. The repeats were carried out on five different sets of solutions, 
















3.1 Modulation of SNARE complex thermal 
stability 
 
The native SNARE complex shows self-assembling properties combined 
with exceptional thermal stability, with a melting temperature around 
85°C (67). This property derives from the highly stable coiled-coil structure 
formed by the four α-helices of the three SNARE proteins. The initial aim 
was to verify whether shortening of VAMP2’s SNARE domain would result 
in a decreased melting temperature of the SNARE complex so that a new 
set of engineered SNAREs could be technologically used to modulate the 
dissociation temperature of protein complexes.  
 
Two versions of VAMP2 were designed: a long (VAMP2-L) and a short one 
(VAMP2-S). SNAP25, syntaxin 1, VAMP2-L and VAMP2-S (see 
Supplementary Table A.1 for their sequences) were expressed and purified 
as described in Section 2.3; affinity purification, elution and FPLC 
chromatography results of all the proteins are shown in Section C of the 
Appendix. 
 
- 63 - 
 
To assess the ability of the recombinant SNAREs to form the expected α-
helical coiled-coil, the proteins were tested using Synchrotron Radiation 
Circular Dichroism (SRCD). When individually tested, the SNARE 
proteins were unstructured as expected, whereas the α-helical structure 
formed when all the three SNAREs were combined, showing a prominent 
peak at 222 nm in the SRCD spectrum (Figure 3.1).  
 
 
Figure 3.1 Far-UV SRCD spectra of SNARE proteins. SNAP25, syntaxin 1 and 
VAMP2-L were tested individually, in pairs and ternary complexes. Each protein was 2 
μM, pH=7.3, at room temperature (20°C). The SNARE complex formed with VAMP2 Long 
is shown in orange and displays the typical α-helix spectrum. The data shown represents 
the average of three different measurements (n=3). 
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To rule out possible interactions between pairs of SNARE proteins, 
SNAP25, syntaxin 1 and VAMP2-L were tested alone and also in pairs. 
When SNAP25 was assessed in combination with syntaxin 1 there was 
some proportion of α-helical structure, suggesting some interaction 
between these components as previously reported (75). When assembled, 
SNAP25, syntaxin, 1, and VAMP2-L produced an SRCD spectrum with a 
clear α-helix pattern, with a double minimum at 208 and 222 nm.  
 
Previous evidence showed that shortening of one of the components of the 
SNARE complex does not prevent complex formation (94). However, it was 
not clear if this modification would affect the complex’s melting 
temperature and, therefore, its stability. SNARE complexes formed by 
SNAP25, syntaxin 1 and VAMP2-S or VAMP2-L were first compared using 
SRCD to analyse their secondary structure at the equivalent 
concentrations. Figure 3.2 shows that both complexes present the α-helix 
pattern, with a double minimum at 208 and 222 nm. The CD signal of the 
VAMP2-S complex is less well defined than the complex formed with 
VAMP2-L, most likely as the shortened VAMP domain leads to a shorter 
α-helical coiled-coil in the overall complex.   
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Figure 3.2 Far-UV SRCD spectra of VAMP2-L and VAMP2-S complexes. Both 
SNARE complexes, formed by SNAP25, syntaxin, and VAMP2 (S or L), were tested under 
the same conditions (2 μM, pH=7.3, 20°C). The peak highlighted at 222 nm corresponds 
to one of the characteristic features of the α-helical secondary structure, and was later 
used to show the disassembly of the complex. The data shown represents the average of 
three different measurements (n=3). 
 
SRCD can be used to show changes in the secondary structure of proteins 
in response to their environment, temperature or pH. A melting 
temperature assay was designed to estimate the thermal stability of 
SNARE complexes with different VAMP2 lengths. Far-UV SRCD spectra 
were recorded while the complexes were gradually heated from 20°C to 
95°C degrees. After plotting the CD signal at 222 nm versus the 
temperature, the melting temperature (Tm) of the complexes was 
calculated as the temperature at which 50% of the maximum intensity at 
222 nm (% unfolding) was lost (Figure 3.3). The results show that the 
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melting temperature dropped significantly from 79.6°C to 42.5°C as a 
consequence of shortening of one helix, suggesting that this is a sufficient 




Figure 3.3 CD temperature scan of VAMP2-L and VAMP2-S SNARE complex. The 
SNARE complex unfolding is expressed here as the percentage of change of CD signal at 
222 nm (over a value of 100 extrapolated at an infinite temperature and corresponding to 
a fully denatured protein). The melting temperature (Tm) is derived by fitting the data to 
a sigmoid and represents the temperature value at which 50% unfolding is achieved. Each 
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3.2 Engineering of binary SNARE complexes 
 
Having established that the SNARE complex’s thermal stability can be 
modulated by shortening of a SNARE domain, we speculated that the 
ability of a shortened SNARE complex to dissociate at relatively low 
temperature could be harnessed to engineer a thermoresponsive interface 
for the release of proteins. The system being binary, rather than ternary, 
would facilitate the immobilisation of one component on a surface, for the 
consequent release of the second moiety. The released molecule could be 
used as a thermoresponsive tag for the fusion of target proteins, for which 
reversible immobilisation on surfaces is required.   
Previous attempts at making binary SNARE complex for protein 
immobilisation on surfaces exist (84). However, no systematic design or 
temperature sensitivity has been reported. 
 
The design of the binary complex was examined to establish an optimal 
combination of SNARE domains and identify a suitable unstructured 
linker to connect the structured domain in their native parallel coiled-coil 
conformation. The naturally occurring linker that connects the first and 
second SNARE domain of native SNAP25 was chosen to link also other 
SNARE domains, such as the SNARE motifs of syntaxin or VAMP. To avoid 
possible formation of unwanted intermolecular disulphide bridges that 
would complicate the interpretation of assembly and disassembly data, all 
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the cysteine residues were converted to alanine. When producing fusions 
of two of the three SNARE proteins together via this linker, many of those 
SNARE fusions (see Table 2.3) were either poorly expressed or difficult to 
elute due to low solubility (see Section D of the Appendix).  
 
Many of the attempts made involved the use of syntaxin 1. As previously 
reported (84), this protein has lower expression in bacteria compared to 
syntaxin 3 (see Table 2.1), which was chosen to replace syntaxin 1: their 
ability to form the SNARE complex were compared performing SRCD, 
along with SNAP25 and VAMP2-L (See Figure 3.4). The use of syntaxin 3 
showed no differences in the formation of the complex, and it was therefore 
selected as one of the final components of the SNARE fusions. 
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Figure 3.4 Far-UV SRCD spectra of  SNARE complexes with different syntaxins. 
The SNARE complexes made of SNAP25, VAMP2-L and either syntaxin 1 or syntaxin 3 
were tested under the same conditions: 20 μM, pH=7.3, 20°C. Both complexes show the 
typical α-helical secondary structure, regardless of the type of syntaxin involved in the 
complex. In red, the spectrum of the Syntaxin 3 alone is shown. The data shown represents 
the average of three different measurements (n=3). 
 
 
The SNARE fusions’ final design took into consideration the previous 
attempts and resulted in the fusion of VAMP2 at the N-terminal and 
syntaxin3 at the C-terminal, separated by the mimic of the SNAP25 linker 
(see Section 2.1.1). Two proteins were obtained, and they were named VS-
L and VS-S, depending on the length of the VAMP2 domain, which had 
equivalent lengths to those tested above.  
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Another SNARE fusion named HH was developed as an alternative to 
SNAP25. HH was designed to match the SNARE motif length of VAMP2-
L and syntaxin (54 amino acids). The C-terminal and N-terminal SNARE 
domains of SNAP25 were truncated and fused using the naturally 
occurring linker between helices of SNAP25 (see Table 2.1). HH was the 
intended partner for the VS SNARE fusions in the formation of the SNARE 
complex. The purification results of HH, VS-L and VS-S can be seen in 
Appendix Figure C.6, C.7 and C.8 respectively.  
 
Tests to assess VS-L and VS-S ability to form a SNARE complex with HH 
were performed using SRCD (see Figure 3.5). Both VS fusion proteins were 
able to form a SNARE complex with HH, as evidenced by the spectra 
suggesting the prominent presence of α-helices, whereas individual HH, 
VS-L and VS-S spectra were compatible with an unstructured 
conformation. 
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Figure 3.5 Far-UV SRCD spectra of VS-L and VS-S complexes and their single 
components. HH, VS-L and VS-S were tested under the same conditions: 8 μM, pH=7.3, 
20°C. They are unstructured when tested individually in solution; when assembled, they 
form a clear α-helical secondary structure, with minima peaks at 208 and 222 nm. The 
data shown represents the average of three different measurements (n=3). 
 
 
These results were in line with those obtained with the ternary equivalents 
of the SNARE complexes, with both the ternary and binary complexes 
containing VAMP2-S showing less α-helical component than those 
containing VAMP2-L. 
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A melting temperature assay was performed with VS-L and VS-S 
complexes (see Section 2.4.2) using SRCD, similarly to those made using 
ternary complexes (Figure 3.6). The Tm of the full-length and shortened 
fusion complexes show a remarkable difference, 79.9° and 43.3°C 
respectively. The melting temperature drop is consistent with the results 
obtained for the ternary complexes’ melting curves. This result suggests 
that the disassembly properties depends on the length of the SNARE 
domains, rather than on their specific arrangement in the form of a ternary 
or binary complex.  
 
 
Figure 3.6 CD temperature scan of VS-L and VS-S SNARE complex. The SNARE 
complex unfolding is here expressed as the percentage of increase of CD signal at 222 nm 
(over a value of 100 extrapolated at an infinite temperature). The melting temperature 
(Tm) is derived by fitting the data to a sigmoid and represents the temperature value at 
which 50% unfolding is achieved. Each data point represents the average of three 
measurements at the given temperature. 
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An alternative linker was designed to rule out any effect of the 
unstructured strand in the formation of the SNARE complex. This artificial 
linker, named k, is a sequence of glycine and serine residues. It was used 
in the design of an alternative VS-L, called VS-L2 (see Table 2.3): SRCD 
spectra of the two SNARE fusions combined with HH were collected and 
compared to test the formation of the SNARE complex (see Figure 3.7).  
 
 
Figure 3.7 Far-UV SRCD spectra of VS-L and VS-L2 complexes. The two HH/VS 
complexes were tested under the same conditions: 8 μM, pH=7.3, 20°C. HH and VS with 
different linkers (VS-L and VS-L”) do not show substantial differences in their ability to 
form the SNARE complex. The data shown represents the average of three different 
measurements (n=3). 
 
Besides, an SRCD melting temperature assay was performed on HH/VS-
L2 to test its thermal stability (see Section 2.4.2). The temperature scans 
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of both VS-L and VS-L2 complexed to HH were used to obtain their melting 
temperatures (see Figure 3.8). The Tm measured for HH/VS-L2 was 79.1°C, 




Figure 3.8 CD temperature scan of VS-L and VS-L2 SNARE complexes. As for 
previous temperature scans, the unfolding of the SNARE complex was measured as an 
expression of increase of CD signal at 222 nm (in percentage, over a value of 100 
extrapolated at an infinite temperature). The temperature value at which 50% unfolding 
is achieved represents the melting temperature (Tm), derived by fitting the data to a 
sigmoid; each data point represents the average of three measurements at the given 
temperature. 
 
The results of Figures 3.7 and 3.8 together show that the alternative linker 
k does not affect the assembly nor the thermal stability properties of the 
binary SNARE complex formed by VS with HH, suggesting that the self-
assembly and melting properties of artificial binary SNARE complex can 
be entirely modulated by only shortening of VAMP2. 
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3.3 Thermoresponsive protein release  
 
As a proof of concept for thermoresponsive release of proteins from a solid 
surface, HH was immobilised on GSH Sepharose beads to assess the 
release of VS-L and VS-S at different temperatures. GSH Sepharose beads 
with cross-linked glutathione (GSH) were used to easily immobilise HH via 
recombinant Glutathione S-Transferase (GST) tag fused at the N-terminal 
of HH (see Figure 3.9 A). 
 
 
Figure 3.9 CD Immobilisation of GST-HH on Sepharose beads and SNARE 
complex formation with VS-L. (A) GST-HH binds to the GSH Sepharose beads. (B) VS-
L (alternatively VS-S, here not represented) is added in solution. (C) After 1 hour, VS-L 
is bound to the GST-HH, forming the SNARE complex. 
 
GSH Sepharose beads are routinely used in pull-down assays to confirm 
known protein-protein interactions (102)  and here the pull-down assay was 
adapted to include an assessment of the interaction at different 
temperatures. Once incubated with VS-L or VS-S (Figure 3.9 B), the ability 
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of the Sepharose-GST-HH beads to capture VS-L and VS-S, thus forming 
the SNARE complex, was tested (Figure 3.9 C). 
After extensive washing, the GSH Sepharose beads were loaded on an SDS-
PAGE gel to visualise the bound proteins (Figure 3.10). The presence of 
VS-L and VS-S bands on lanes containing GST-HH proved that there is 
binding between HH and both VSs. A negative control where GST without 
HH fusion was incubated with VS was used to prove that the binding is 
actually specific between HH and VSs. The lack of any VS band in the 
control confirms that no interaction occurs between GST and both VSs.  
 
 
Figure 3.10 SDS-PAGE gel of the pull-down of VS-L and VS-S by functionalised 
Sepharose beads. Lane 1 and 2 show Sepharose-GST-HH incubated with excess VS-S 
(1) and VS-L (2). As shown by the arrows on the left, the band on both lanes corresponds 
to GST-HH (45.3 kDa), and the other bands correspond to the molecular weight of VS-L 
(21.3 kDa, lane 2) and VS-S (17.2kDa, lane 1) respectively. Lane 3 and 4 are negative 
controls where Sepharose-GST with no HH was incubated with an excess of VS-S (3) and 
VS-L (4). In these lanes there is only one band indicated by the arrow on the left, 
corresponding to GST’s mass (28.6 kDa), whereas no pull-down of VS was observed. PM = 
protein marker with relative masses of the standards. 
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These results are consistent with the results observed for binary SNAREs 
in solution obtained using SRCD (Figure 3.5). It is essential to point out 
that, whereas it is possible to determine the secondary structure of protein 
immobilised on surfaces using SRCD (99,103,104), this technique would not 
be applicable in this exact design. The structure of the GST tag has several 
alpha-helices which would contribute to the CD peaks at 208 and 222 nm, 
regardless of the assembly status of the SNARE domains, so the 
interpretation of the results would not be as straightforward as it was for 
the SNAREs in solution.  
Since the amount of proteins used in these experiments is small ( 2-10 μM), 
VS-L and VS-S were fluorescently labelled with maleimide-activated Cy5 
to make it easier to detect their capture and release from HH (Figure 3.11).  
 
 
Figure 3.11 Schematic representation of the VS-L-Cy5 and VS-S-Cy5 constructs. 
Cylinders represent SNARE domains: VAMP2 in blue, syntaxin 3 in red; the green line 
represents the naturally occurring linker between the two α-helices of SNAP25, used here 
to combine VAMP2 and syntaxin3 in a single polypeptide. At the C terminal of VAMP2 
(both long and short), the presence of a cysteine allows the modification via chemical cross-
linking with a Cy5-maleimide fluorophore molecule. 
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VAMP2-L and VAMP2-S, and consequently VS-L and VS-S, carry a 
cysteine residue to facilitate site-specific chemical cross-linking of the 
fluorophore to the thiol group of such amino acid. Neither native VAMP 
nor syntaxin carry a cysteine residue in the proximity of the SNARE motif, 
so the amino acid was introduced at the end of VAMP2’s sequence. VS is a 
SNARE fusion arranged as VAMP2-linker-syntaxin3; therefore, the 
cysteine is positioned at one-third of the overall sequence (See Figure 3.11).  
 
After purification by size exclusion chromatography, the fluorescently-
labelled proteins were run on an SDS-PAGE gel and analysed using 
Odyssey (LI-COR Imaging System). The gel was imaged at both 600 and 
700 nm channels: Cy5 absorbance peak is at 649 nm and its emission is 
visible at 700 nm. The 600 nm channel was used to highlight some of the 
bands of the protein marker (Figure 3.12).   
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Figure 3.12 SDS-PAGE gel of VS-L and VS-S labelled with maleimide-activated 
Cy5. On the left, the Coomassie-stained gel shows the bands corresponding to VS-L-Cy5 
and VS-S-Cy5, indicated by the labels. The presence of a double band is due to the different 
migration of the labelled proteins, behaving as a slightly higher molecular weight protein 
(clearly visible in lane 2). The conjugation efficiency can be therefore estimated as around 
~50%. The high molecular weight bands (between 37 and 50 kDa) are likely VS-L and VS-
S dimers formed by disulphide bonds between unreacted thiols on the cysteine residues. 
PM stands for protein marker (Precision Plus, BioRad), with relative masses on the left 
side of the gel. On the right, the same gel imaged with Odyssey Imaging System (LI-COR 
Biosciences) to highlight the fluorescent properties of the two constructs. 600 nm and 700 
nm channel in red and blue, respectively. 
 
To assess temperature response of SNARE complexes immobilised on GSH 
Sepharose beads, a large volume of complexes were assembled; fractions of 
the fully-formed Sepharose beads-GST-HH and VS complexes were 
incubated at different temperatures. GST-HH was tested at a 
concentration of 3 μM, adding 5μM of each labelled VS to saturate the 
system. Once the excess of unbound protein was removed, the residual Cy5 
fluorescence intensity was measured, representing the quantity of VS 
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retained at any set temperature. At the highest temperature (80°C), 
neither VS-L-Cy5 nor VS-S-Cy5 were bound to the resin. While 60% of VS-
L-Cy5 was still bound to the surface at 50°C, the amount of VS-S-Cy5 at 
the same temperature was negligible, as most of VS-S-Cy5 was abruptly 
released below that temperature (Figure 3.13). 
 
 
Figure 3.13 VS-L-Cy5 and VS-S-Cy5 residual fluorescence intensity. The data in 
this plot represent the residual fluorescence measured on Sepharose-GST-HH bound to 
VS-L-Cy5 and VS-S-Cy5 after incubation at different temperatures. Data points and error 
bars represent, respectively, the average of three measurements and standard deviation. 
GST-HH was 3 μM, while both VS were used in excess, 5 μM each. 
 
The different response to the temperature of the two surface-immobilised 
complexes is consistent with what observed for SNAREs in solution, 
enforcing once more that the disassembly properties of the engineered 
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complexes primarily depend on the length of the VAMP2 domain only. 
However, GST itself is sensitive to high temperatures: its Tm is around 
70°C, but tends to aggregate even below this threshold (105). Therefore, the 
release of VS-L above 60°C may be due to the disruption of the bond 
between GST and the GSH Sepharose beads. 
 
To assess the capture-and-release properties of the Sepharose-GST-HH/VS 
system over several cycles of heating and cooling at room temperature 
(20°C), the pull-down was repeated, but the retention of Cy5 fluorescence 
was measured after up to 4 cycles of heating and cooling (Figure 3.14). The 
heating temperature was set depending on the length of VS: 80°C was used 
for VS-L and 50°C for VS-S.  
 
The results show that the latter complex was still functional after four 
cycles. This outcome highlights that the use of natively unstructured 
proteins like the SNARE domains allows the engineering of an 
immobilisation system that is insensitive to denaturation or aggregation of 
the immobilisation tags and can be therefore regenerated. 
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Figure 3.14 VS-L-Cy5 and VS-S-Cy5 residual fluorescence intensity after 
heating-cooling cycles. Fluorescence intensity of captured VS-S-Cy5 and VS-L-Cy5 
after Sepharose-GST-HH was heated and cooled for 0 to 4 cycles. GST-HH was 
immobilised on GSH Sepharose beads; when incubated with VS-L-Cy5 the release 
temperature used was  80°C, whereas 50°C was used for VS-S-Cy5. Sepharose-GST-HH 
ability to capture and release VSs is expressed as residual fluorescence intensity after n 




However, the interface with VS-L that was heated to 80°C lost a 
considerable amount of fluorescence intensity after just one cycle. In the 
absence of a control test with GST alone, it was assumed that this behavior 
was due to the denaturation of GST and loss of binding ability, suggesting 
that the assay to test regeneration cannot be performed at high 
temperatures. The future addition of GST only as a control may clarify its 
role in the capture-and-release of VS-L from GST-HH.  
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As our focus was on the optimisation of a SNARE complex for 
thermoresponsive release, rather than on the strategy for the 
immobilisation on the surface, we concluded that the development of a 
binary SNARE system was entirely successful. It consisted of an 
immobilisation protein named HH that could be regenerated, and 
thermoresponsive tags VS-S and VS-L that could be released in a 
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4. DISCUSSION AND CONCLUSIONS 
 
The design of a thermoresponsive interface began with the investigation of 
the Rattus norvegicus neuronal SNARE complex and its structural 
features. The complex is a parallel coiled-coil structure, and its formation 
is possible thanks to the SNARE motif, which assumes an α-helical 
structure only when combined with the other SNARE motif domains as an 
arrangement of several hydrophobic layers in the direction of the core 
complex.  
The remarkable strength and peculiarity of the SNARE complex have 
proven fundamental for the design of a thermoresponsive interface. The 
recombinant SNAREs intended for this project focused on the preservation 
of the SNARE motif, eliminating the additional domains from the designed 
sequences.  
 
Newly designed syntaxin 1 and VAMP2 had matching length, which covers 
the 54-amino acid long SNARE motif strand. First, recombinant SNAP25, 
syntaxin 1 and VAMP2 were expressed and purified in E. coli and used to 
characterise the thermal stability of the full-length SNARE complex in 
solution. A truncated version of VAMP, reducing its SNARE motif from 54 
to 25 amino acids, was developed to test the SNARE complex thermal 
stability since there was evidence to support that shortening one helix still 
allows the formation of the complex (60,94). The ionic layer was removed 
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from the VAMP2-S to rule out disturbances of pH and charge when 
interpreting the results. For the first time, VAMP was shortened to roughly 
half of its native size; the ionic layer was excluded to examine the 
association and disassociation of the complex. SNARE proteins were tested 
individually and in pairs; Far-UV SRCD spectra confirmed that single 
proteins are unstructured (Figure 3.1) and that there is partial assembly 
only in the SNAP25/syntaxin 1 pair, as previously observed (75). 
The choice of shortening VAMP2 instead of syntaxin or one of the SNARE 
motifs of SNAP25 derived from the knowledge that it is the last protein, 
among the three mentioned, to assemble into the SNARE complex. It would 
be interesting to study the differences when shortening a different α-helix, 
and further explore the role of the ionic layer residue if left on the truncated 
version.  
 
Far-UV SRCD spectra of both complexes containing SNAP25, syntaxin 1 
and either VAMP2-L or VAMP-S (Figure 3.2) showed the typical α-helical 
spectrum shape; however, the SNARE complex formed with VAMP-S 
revealed a less intense CD signal. The reduction of the α-helical component, 
compared to the one with VAMP-L, can be explained with the reduced size 
of the structured domains.  
Moreover, using SRCD temperature scans, it was possible to obtain a 
melting temperature curve. From the 79.6°C disassembly temperature of 
the long VAMP complex, the SNARE complex with the truncated VAMP 
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dropped to 42.5°C (melting temperatures extracted from Figure 3.3). It is, 
therefore, possible to modulate the SNARE complex’s melting temperature 
by shortening of SNARE domains while maintaining the structural 
features that allow self-assembly.  
 
 
Since the ultimate goal of the project was the immobilisation of a protein 
system, the SNARE complex would benefit from being binary rather than 
ternary. One protein could be immobilised on a surface of interest, while 
the thermoresponsive tag for controlled release could be fused to a protein 
of interest (81). The modular approach developed to repeatedly clone 
different combinations of SNARE domains, starting from a limited number 
of SNAREs’ inserts, was crucial to transition from a ternary to a binary 
SNARE complex.  
A new version of SNAP25 was built truncating its SNARE motifs (on their 
respective C-terminal) to match the length of VAMP and syntaxin. The 
unstructured linker between the two α-helices was preserved to connect 
them; the complete recombinant protein, consisting of three fragments 
(helix one, linker and helix two) was named HH to highlight the presence 
of two helices.  
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To preserve the thermal stability properties of the SNARE complexes 
formed with the long and short VAMP, while reducing it to a binary system, 
VAMP and syntaxin were fused together. A polypeptide separates the N-
terminal of VAMP2 and the C-terminal of syntaxin motifs; this linker is 
the one found between the two helices of SNAP25. The new VAMP2-
syntaxin (VS) recombinant proteins were named VS-L and VS-S, differing 
on the length of VAMP2 domain (54 or 25 amino acids long, respectively). 
 
These fusion proteins were successfully expressed in E. coli and purified. 
Many SNARE fusions were either poorly expressed or difficult to elute due 
to low solubility; the modular cloning approach developed to link together 
separate SNARE domains (see Section 2.2.3) was essential to try different 
combinations of SNAREs in a methodical way. Of the numerous attempts 
to express the three SNARE proteins into a binary construct, VSs were the 
successful ones. Previous studies showed that syntaxin 1 fusions have 
lower expression in bacteria (84); consequently, syntaxin 3 replaced 
syntaxin 1 in the design of the VS fusion proteins. SRCD was performed on 
syntaxin 1 and 3, individually and along with VAMP2 and SNAP25. Far-
UV spectra confirmed that there are no differences between syntaxin 1 and 
syntaxin 3 in their ability to form a SNARE complex (Figure 3.4).     
 
HH and VS are partners in the formation of the SNARE complex; circular 
dichroism spectroscopy was used to assess their assembly properties. HH, 
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coupled with both VS-L and VS-S, was able to form the SNARE complex 
analogously to their ternary counterpart (Figure 3.5). Moreover, the 
SNARE fusions are unstructured when alone, acquiring an α-helical 
conformation only when together. 
The melting temperatures of HH/VS-L and HH/VS-S binary complexes 
were measured using SRCD; the obtained values were very similar to the 
ones obtained for the ternary complexes. HH/VS-L disassembles at 79.9°C 
(the ternary counterpart at 79.6°C), and HH/VS-S loses its α-helicity at 
43.3°C (against the 42.5°C recorded for the ternary shortened SNARE 
complex (Figure 3.6).  
 
These results confirmed that, by shortening one helix, it is possible to 
manipulate the SNARE complex’s melting temperature; in particular, the 
effort of reaching a Tm compatible with the use in vivo was successful. 
Hyperthermia studies conducted in the past showed that the body can 
withstand local temperatures around 45°C, temperature at which VS-S is 
able to be released from a surface. The combination of the 
thermoresponsive properties of VS-S with designed nanocarriers would be 
useful for the development of hyperthermia-directed protein therapeutics. 
The thermoresponsive protein interface obtained, VS-S, may contribute to 
the growing interest towards magneto-responsive local release of 
therapeutics. 
  
- 89 - 
 
The VS constructs carry the native unstructured linker existing between 
SNAP25’s SNARE motifs; to exclude possible interactions between HH and 
the linker, an alternative one made of a glycine and serine sequence was 
inserted between VAMP-L and syntaxin 3, obtaining a new construct called 
VS-L2. VS-L and VS-L2 were analysed with circular dichroism 
spectroscopy: both spectra and temperature scans (Figure 3.7 and 3.8, 
respectively) indicated no differences between the two fusion proteins. 
These results prove that the new SNARE constructs preserved similar 
thermal stability properties compared to their original ternary 
counterparts. Thanks to the re-arrangement of SNARE domains, including 




All the SNARE constructs were expressed as a Glutathione S-Transferase 
(GST) tagged proteins (on its C-terminal); therefore, every recombinant 
protein had a high affinity for GST-modified resins, making them an 
appropriate method to purify the resulting recombinant proteins from the 
bacterial lysate (106). The GST affinity tag could then be removed by 
thrombin cleavage or retained for other purposes, as to easily immobilise 
GST-tagged proteins on a surface. Other materials may be more suitable 
for the immobilisation of the SNARE recombinants in order to release them 
from a surface, as peptides with high affinity for carbon- and silica-based 
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materials (107,108); however, the GST-tag was a convenient way to achieve 
proof-of-concept, while other methods will be investigated in the future.  
Considering that the ultimate goal was the immobilisation and 
temperature-mediated release of the binary SNARE complex from a 
surface, HH was purified as a GST-tagged protein and immobilised on GSH 
Sepharose beads. The GST/GSH interaction showed high affinity and 
remarkable stability; together with the high solubility of the GST tag, this 
system becomes suitable for strong immobilisation of recombinant proteins 
on GSH-modified resins or other surfaces, such as plates, biosensors, 
magnetic beads. Previous studies showed that GST has a high affinity to 
gold, and can thus be used to decorate gold nanoparticles (94,97). 
 
The ability of GST-HH to capture its VS partner at different temperature 
was analysed with a pulldown experiment. Sepharose-GST-HH was able 
to bind both VS-L and VS-S; in addition, the inability of Sepharose-GST to 
bind the VS constructs confirmed the specific binding existing between HH 
and VSs, ruling out possible interference by GST or the surface itself 
(Figure 3.10). 
The pulldown results were evaluated with an SDS-PAGE; this method, 
however, provides only a qualitative or semi-quantitative estimate of the 
protein amount captured by the functionalised beads. To allow an easier 
detection of the captured protein, the two VS constructs were then 
fluorescently labelled with Cy5-maleimide. The Cy5 fluorophore molecule 
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was connected the VS constructs via chemical cross-linking; the two 
VAMP-syntaxin fusion proteins carry a cysteine residue on VAMP2’s C-
terminal (Figure 3.11), explicitly introduced to allow fluorescence-
labelling. VS-L-Cy5 and VS-S-Cy5 were then purified and run on SDS-
PAGE (Figure 3.12). 
 
A pulldown assay similar to the one above was carried out with fluorescent 
VSs. Sepharose-GST-HH was incubated with an excess of either VS-L-Cy5 
or VS-S-Cy5 at different temperatures to saturate the system. After 
extensive washing at the same temperature to remove the unbound 
protein, the residual Cy5 fluorescence was measured to assess the 
proportion of captured protein, as indicated by the intensity of the 
fluorescent signal of VS still bound on Sepharose-GST-HH at a given 
temperature. Above 80°C neither VS was bound the beads; at 50°C, most 
of VS-L-Cy5 was still bound to the surface, while the fluorescence intensity 
of VS-S-Cy5 dropped abruptly (Figure 3.13). Some of the residual 
fluorescence of both VSs was lost below 35°C, possibly due to incorrect 
alignment or wrong stoichiometry between SNARE domains of VS and HH 
(84). Further experiments may be conducted lowering the concentration of 
GST-HH to avoid the incorrect formation of the SNARE complex with 
syntaxin and VAMP2 belonging to different VS fusions. 
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The lack of a control, performed with GST only, makes this method 
unreliable for measurements over ~60°C, as this is the near the assumed 
melting temperature for GST. The release of VS-L from Sepharose-GST-
HH is dependent on GST and its ability to bind GSH Sepharose beads. 
When this bound is lost, it is not possible to assess at what temperature 
VS-L and GST-HH complex unfolds. Similar experiments could be 
performed using a resin other than GSH-Sepharose: for example, cyanogen 
bromide-activated-Sepharose, which provides covalent cross-linking to the 
protein of interest. 
However, all the data discussed above proved that HH could capture and 
release both VSs when immobilised on a surface (Sepharose GSH beads). 
To understand if such property could be maintained after numerous cycles 
of heating and cooling, both Sepharose-GST-HH/VS systems were tested. 
Since they respond to different temperatures, the molecular interface 
carrying the VS-S-Cy5 was heated to 50°C, while the one with VS-L-Cy5 
reached 80°C; both systems were heated four times and cooled at 20°C after 
each cycle (Figure 3.14).  
 
The behaviour of the two interfaces was very different, as Sepharose-GST-
HH/VS-S-Cy5 showed no significant changes after four cycles. The moiety 
carrying VS-L and heated at high temperature showed a loss of 
fluorescence intensity after one cycle. SNARE mimics are naturally 
unstructured and unlikely to denature and lose function permanently; 
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however, as assumed before, this result could be attributed to the partial 
loss of function of GST at temperatures higher than 56°C. Moreover, this 
result is consistent with the trend observed before (Figure 1.13), where VS-
L-Cy5’s release rate increased when the temperature was over 50°C. 
Future experiments may direct the attention on GST and how to avoid its 
interference when studying the release of VS-L at high temperatures. 
 
The results obtained confirmed that the engineered HH/VS binary complex 
is thermoresponsive, and it preserves its thermal stability properties when 
immobilised on a surface; it can, therefore, be potentially used as an 
interface to release proteins from a surface when triggered by a local 
increase of temperature. 
Protein-protein interactions often lead to protein aggregation and require 
substantial optimisations effort (109); on the contrary, here, no irreversible 
protein aggregation was observed between the SNARE mimics. 
Interestingly, the designed SNARE constructs were able to refold when 
immobilised on a surface; besides, the possibility to regenerate the surface 
after subsequent cycles of capture and release was here demonstrated. 
These remarkable properties suggest that the interactions involved in the 
formation of the SNARE complex are fully reversible and therefore 
compatible with dynamic and programmable surfaces involving 
biomolecules (110).  
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The design of this thermoresponsive interface originated after extensive 
study of the previous engineering of the coiled-coil structure of the 
neuronal SNARE complex and other coiled-coil motifs (111). The 
background study allowed the modulation of the disassembly temperature 
down to reasonable physiological conditions for in vivo applications, such 
as the use of engineered hyperthermia-directed therapeutics (112).  
 
Hyperthermia was used with thermoresponsive polymers before, as in the 
case of hybrid peptide-lipid vesicles. These nanoscale thermoresponsive 
carriers were tested in vivo, with the successful release of doxorubicin after 
hyperthermia treatment (113). In Europe, the treatment of glioblastoma 
already utilises magnetic hyperthermia: iron oxide nanoparticles are used 
to induce a local increase of temperature (114). The latter could be a 
promising method for local release of therapeutics in response to a 
magnetic stimulus, towards which the thermoresponsive protein interface 
described here may contribute. 
 
Nanoparticle-based systems for local drug delivery are found not only 
among the magnetic responsive materials but also among those who retain 
the ability to absorb energy in the near-infrared (NIR) spectrum. NIR can 
be used to trigger a local and controlled increase of temperature in vivo; 
the advantage of these systems is that NIR light is absorbed in minimal 
part by tissues, ad it can penetrate in the micro- and centi-scale, allowing 
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photo-thermal drug release (27). In the last twenty years, numerous 
research groups developed gold nanorods with a strong absorbance in the 
NIR range working both in vitro and in vivo (115,116): these systems can be 
triggered to change their conformation in response to NIR irradiation, 
releasing biomolecules. The thermoresponsive protein release tag 
properties reported here may be a suitable interface for magnetic 
responsive and photo-thermal therapy. 
 
To exploit the use of HH/VS-S as an interface for drug delivery, the binary 
complex would need further characterisation, both in vitro and in vivo. 
First, it is essential to find a suitable carrier, and how to best bind HH to 
it. Secondly, a refined tuning of the ability of such engineered carrier to 
capture and release its VS counterpart needs to be carried out. As for the 
in vivo studies, extensive work may be carried out to study the interface 
behaviour in the bloodstream, with particular attention to interactions 
with plasma proteins and/or opsonisation to avoid HH/VS inactivation and 
quick degradation.  
The surface chemistry of nanomaterials used for drug delivery can be tuned 
so that adhesion of plasma-protein is minimised and the size of the 
nanoparticle carrier can be selected big enough to limit renal clearance. 
Furthermore, modifications such as PEGylation may increase its plasma 
half-life; if intended to be used for targeted delivery, an additional 
targeting system (a specific protein sequence, or a small molecule) could be 
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added to the system. However, the conjugation of further functional 
protein, as described here, may change the surface properties 
substantially. Therefore protein-nanoparticle conjugates have to be tested 
and considered on a case-by-case base, as it is not possible to predict how a 
specific protein would interact with plasma proteins and renal clearance 
mechanism. 
 
The results described in this thesis suggest that the release temperature 
of an engineered SNARE complex can be modulated by changing the length 
of one SNARE motif. Previous studies showed that, by shortening one α-
helix, it was possible to weaken the chemical stability of the SNARE 
complex. However, this research did not provide any data on the complex’s 
thermal stability; hence the analysis carried out in this work. The 
truncation of a SNARE motif proves that it would be possible to obtain a 
wide array of thermoresponsive tags reacting to temperatures in the range 
of 43-80°C. Alternatively, a similar approach could be used to modulate its 
pH sensitivity. 
 
To fully develop the potential of these new interface proteins, the 
immobilisation on surfaces other than GSH Sepharose beads should be 
explored further. For example, GST could be replaced by available peptides 
with affinity to specific materials; alternatively, the SNAREs could be 
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directly linked to a surface using available chemical bioconjugation 
methods (117,118). 
 
Once fused to thermoresponsive VS, recombinant proteins of interest could 
be used for immobilisation and release from HH-modified materials, 
regardless of HH’s immobilisation method. On the other hand, HH-
activated materials could be used for the immobilisation and release of any 
VS-tagged recombinant protein, emphasising the modularity and 
flexibility of the system described here. Thermoresponsive SNARE-derived 
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A. Protein sequences 
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Table A.1 SNARE protein sequences. Amino acid sequences of recombinant proteins 
and their molecular weight. The amino acid sequences are represented in different colour: 
red = syntaxin SNARE domains, blue = VAMP2 SNARE domains, dark green = N-
terminal SNARE domain (H1) of SNAP25, light green = C-terminal H2 domain of 
SNAP25, purple = linker l (natural linker occurring between SNARE domains of 
SNAP25), yellow = artificial linker k, light blue = GST, black = glycine and serine (GS) 
residues originated from the cloning strategy. The cysteine-to-alanine substitutions and 
the extra cysteine residues introduced for chemical cross-linking are highlighted in yellow 
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B. DNA sequencing data 
 
DNA sequencing was used to determine the sequence of plasmids obtained 
from plasmid cloning (See Section 2.2.7). 0.5 μg of each sample (100ng/μl, 
5μl) were sent to Source Bioscience for sequencing, using suitable primers 
for pGEX-KG, both forward and reverse. 
All the constructs were successfully cloned, as seen in Figures B.1-8.  
 
 
Figure B.1 Alignment of the theoretical and experimental sequence of syntaxin 
1. SYNT1_T was obtained in silico (Theoretical, T) from reverse translation of syntaxin 1 
sequence. SYNT1_E is the result of the sequencing (Source Bioscience) of the plasmid 
obtained in vitro (Experimental, E). They were aligned with Blastn (NCBI) to verify their 








Figure B.2 Alignment of the theoretical and experimental sequence of syntaxin 
3. SYNT3_T was obtained in silico (Theoretical, T) from reverse translation of syntaxin 3 
sequence. SYNT3_E is the result of the sequencing (Source Bioscience) of the plasmid 
obtained in vitro (Experimental, E). They were aligned with Blastn (NCBI) to verify their 
validity: there are 100% identity and 0% gaps between the two sequences. 
 
 
- 120 - 
 
 
Figure B.3 Alignment of the theoretical and experimental sequence of VAMP2-
L. VAMP2-L_T was obtained in silico (Theoretical, T) from reverse translation of VAMP2-
L sequence. VAMP2-L_E is the result of the sequencing (Source Bioscience) of the plasmid 
obtained in vitro (Experimental, E). They were aligned with Blastn (NCBI) to verify their 
validity: there are 100% identity and 0% gaps between the two sequences. 
 
 
Figure B.4 Alignment of the theoretical and experimental sequence of VAMP2-
S. VAMP2-S_T was obtained in silico (Theoretical, T) from reverse translation of VAMP2-
S sequence. VAMP2-S_E is the result of the sequencing (Source Bioscience) of the plasmid 
obtained in vitro (Experimental, E). They were aligned with Blastn (NCBI) to verify their 
validity: there are 100% identity and 0% gaps between the two sequences. 
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Figure B.5 Alignment of the theoretical and experimental sequence of HH. HH_T 
was obtained in silico (Theoretical, T) from reverse translation of H1, linker l and H2 from 
SNAP25 sequence. HH_E is the result of the sequencing (Source Bioscience) of the 
plasmid obtained in vitro (Experimental, E). They were aligned with Blastn (NCBI) to 
verify their validity: there are 100% identity and 0% gaps between the two sequences. 
- 122 - 
 
 
Figure B.6 Alignment of the theoretical and experimental sequence of VS-L. VS-
L_T was obtained in silico (Theoretical, T) from reverse translation of VAMP2-L, linker l 
and syntaxin 3 as a fusion complex. VS-L_E is the result of the sequencing (Source 
Bioscience) of the plasmid obtained in vitro (Experimental, E). They were aligned with 
Blastn (NCBI) to verify their validity: there are 100% identity and 0% gaps between the 
two sequences. 
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Figure B.7 Alignment of the theoretical and experimental sequence of VS-S. VS-
S_T was obtained in silico (Theoretical, T) from reverse translation of VAMP2-S, linker l 
and syntaxin 3 as a fusion complex. VS-S_E is the result of the sequencing (Source 
Bioscience) of the plasmid obtained in vitro (Experimental, E). They were aligned with 
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Figure B.8 Alignment of the theoretical and experimental sequence of VS-L2. VS-
L2_T was obtained in silico (Theoretical, T) from reverse translation of VAMP2-L, linker 
k and syntaxin 3 as a fusion complex. VS-L2_E is the result of the sequencing (Source 
Bioscience) of the plasmid obtained in vitro (Experimental, E). They were aligned with 
Blastn (NCBI) to verify their validity: there are 100% identity and 0% gaps between the 
two sequences. 
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C. Protein purification 
 
After low-temperature expression in BL21-gold (DE3) pLysS cells (See 
Section 2.3), all the proteins were purified through affinity purification on 
GSH Sepharose beads, followed by size exclusion chromatography. 
  
- Syntaxin 1 
 
Figure C.1 Purification of syntaxin 1. A) SDS-PAGE of the affinity purification on 
GSH beads and thrombin cleavage of Syntaxin 1. The bacterial lysate was incubated with 
GSH Sepharose beads, leading to the immobilisation of GST-syntaxin 1 onto them; the 
elution of syntaxin 1, obtained by thrombin cleavage, was not well visible on the SDS-
PAGE due to small protein size (lane E, band below 10kDa). Abbreviations: SN = 
supernatant, FT = flow through, B = beads, E = eluate, BAC = beads after cleavage. B) Size 
exclusion chromatography chromatogram; red numbers on the bottom indicate the 
fractions collected by the ÄKTA Pure chromatography system (GE Healthcare). On the X-
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axis, the elution volume (in ml); on the Y-axis, the UV-light absorption at 280nm, 
expressed in mAU (milli Absorbance Units). C) SDS-PAGE of the fractions collected by 




Figure C.2 Purification of VAMP2-L. A) SDS-PAGE of the affinity purification on GSH 
beads and thrombin cleavage of VAMP2-L. The bacterial lysate was incubated with GSH 
Sepharose beads, leading to the immobilisation of GST-VAMP2-L onto them; the elution 
of VAMP2-L was obtained by thrombin cleavage. In the eluate E, other than the band 
corresponding to VAMP2-L (~6.6kDa), there are two more bands at 25 and ~75kDa. 
Abbreviations: SN = supernatant, FT = flow through, B = beads, E = eluate, BAC = beads 
after cleavage. B) Size exclusion chromatography chromatogram; red numbers on the 
bottom indicate the fractions collected by the ÄKTA Pure chromatography system (GE 
Healthcare). On the X-axis, the elution volume (in ml); on the Y-axis, the UV-light 
absorption at 280nm, expressed in mAU (milli Absorbance Units). C) SDS-PAGE of the 
fractions collected by the FPLC incubated with 5μM TCEP to avoid the formation of 
dimers. In lane F6, the two bands found in the eluate E, separated from the protein of 
interest: this gel confirms that VAMP2-L is mostly in F7 and F8. 




Figure C.3 Purification of VAMP2-S. A) SDS-PAGE of the affinity purification on GSH 
beads and thrombin cleavage of VAMP2-S. The bacterial lysate was incubated with GSH 
Sepharose beads, leading to the immobilisation of GST-VAMP2-S onto them; the elution 
of VAMP2-S was obtained by thrombin cleavage. VAMP2-S’s molecular weight is 3.3kDa, 
but it migrated mostly as a dimer in the eluate (E) lane. Abbreviations: SN = supernatant, 
FT = flow through, B = beads, E = eluate, BAC = beads after cleavage. B) Size exclusion 
chromatography chromatogram; red numbers on the bottom indicate the fractions 
collected by the ÄKTA Pure chromatography system (GE Healthcare). On the X-axis, the 
elution volume (in ml); on the Y-axis, the UV-light absorption at 280nm, expressed in 
mAU (milli Absorbance Units). C) SDS-PAGE of the fractions collected by the FPLC and 
incubated with 5μM TCEP to avoid the formation of dimers. This gel confirms that 
VAMP2-S is in F7 and F8. 
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- Syntaxin 3 
 
Figure C.4 Purification of syntaxin 3. A) SDS-PAGE of the affinity purification on 
GSH beads and thrombin cleavage of syntaxin 3. The bacterial lysate was incubated with 
GSH Sepharose beads, leading to the immobilisation of GST-syntaxin 3 onto them; the 
elution of syntaxin 3 was obtained by thrombin cleavage (6.4kDa, lane E). The expression 
and elution of syntaxin 3 are better than the one from syntaxin 1 (Figure C.1). 
Abbreviations: SN = supernatant, FT = flow through, B = beads, E = eluate, BAC = beads 
after cleavage. B) Size exclusion chromatography chromatogram; red numbers on the 
bottom are the fractions collected by the ÄKTA Pure chromatography system (GE 
Healthcare). On the X-axis, the elution volume (in ml); on the Y-axis, the UV-light 
absorption at 280nm, expressed in mAU (milli Absorbance Units). C) SDS-PAGE of the 








Figure C.5 Purification of SNAP25. A) SDS-PAGE of the affinity purification on GSH 
beads and thrombin cleavage of SNAP25. The bacterial lysate was incubated with GSH 
Sepharose beads, leading to the immobilisation of GST-SNAP25 onto them; the elution of 
SNAP25 was obtained by thrombin cleavage. The elution was not 100% efficient, as there 
is still some SNAP25 on the final beads (BAC). In spite of its molecular weight being 
23.3kDa, SNAP25 migrates as a heavier protein, approximately 28kDa.  Abbreviations: 
SN = supernatant, FT = flow through, B = beads, E = eluate, BAC = beads after cleavage. 
B) Size exclusion chromatography chromatogram; red numbers on the bottom are the 
fractions collected by the ÄKTA Pure chromatography system (GE Healthcare). On the X-
axis, the elution volume (in ml); on the Y-axis, the UV-light absorption at 280nm, 
expressed in mAU (milli Absorbance Units). C) SDS-PAGE of the fractions collected by 
the FPLC. This gel confirms that SNAP25 is mostly in F6. 
 
 




Figure C.6 Purification of HH. A) SDS-PAGE of the affinity purification on GSH beads 
and thrombin cleavage of HH. The bacterial lysate was incubated with GSH Sepharose 
beads, leading to the immobilisation of GST-HH onto them; the elution of HH was 
obtained by thrombin cleavage. As its equivalent SNAP25, it migrates as a slightly higher 
molecular weight protein (HH weighs 20.3kDa). Abbreviations: SN = supernatant, FT = 
flow through, B = beads, E = eluate, BAC = beads after cleavage. B) Size exclusion 
chromatography chromatogram; red numbers on the bottom are the fractions collected by 
the ÄKTA Pure chromatography system (GE Healthcare). On the X-axis, the elution 
volume (in ml); on the Y-axis, the UV-light absorption at 280nm, expressed in mAU (milli 
Absorbance Units). C) SDS-PAGE of the fractions collected by the FPLC. This gel confirms 
that HH is mostly in F6 and F7; the high molecular weight band present in the eluate (E, 
gel A) is in lane F5. 
 
 




Figure C.7 Purification of VS-L. A) SDS-PAGE of the affinity purification on GSH 
beads and thrombin cleavage of VS-L. The bacterial lysate was incubated with GSH 
Sepharose beads, leading to the immobilisation of GST-VS-L onto them; the elution of VS-
L (21.3kDa) was obtained by thrombin cleavage. Abbreviations: SN = supernatant, FT = 
flow through, B = beads, E = eluate, BAC = beads after cleavage. B) Size exclusion 
chromatography chromatogram; red numbers on the bottom are the fractions collected by 
the ÄKTA Pure chromatography system (GE Healthcare). On the X-axis, the elution 
volume (in ml); on the Y-axis, the UV-light absorption at 280nm, expressed in mAU (milli 
Absorbance Units). C) SDS-PAGE of the fractions collected by the FPLC incubated with 
5μM TCEP to avoid the formation of dimers. This gel confirms that VS-L is mostly in F5 








Figure C.8 Purification of VS-S. A) SDS-PAGE of the affinity purification on GSH 
beads and thrombin cleavage of VS-S. The bacterial lysate was incubated with GSH 
Sepharose beads, leading to the immobilisation of GST-VS-S onto them; the elution of VS-
S (17.2kDa) was obtained by thrombin cleavage. The elution was not 100% efficient, as 
some VS-S was still immobilised on the final beads (BAC). Abbreviations: SN = 
supernatant, FT = flow through, B = beads, E = eluate, BAC = beads after cleavage. B) Size 
exclusion chromatography chromatogram; red numbers on the bottom are the fractions 
collected by the ÄKTA Pure chromatography system (GE Healthcare). On the X-axis, the 
elution volume (in ml); on the Y-axis, the UV-light absorption at 280nm, expressed in 
mAU (milli Absorbance Units). C) SDS-PAGE of the fractions collected by the FPLC 
incubated with 5μM TCEP to avoid the formation of dimers. This gel confirms that VS-S 








Figure C.9 Purification of VS-L2. A) SDS-PAGE of the affinity purification on GSH 
beads and thrombin cleavage of VS-L2. The bacterial lysate was incubated with GSH 
Sepharose beads, leading to the immobilisation of GST-VS-L2 onto them; the elution of 
VS-L2 was obtained by thrombin cleavage. VS-L2 migrates as a ~20kDa protein, even if 
its molecular weight is 16.1kDa. Abbreviations: SN = supernatant, FT = flow through, B 
= beads, E = eluate, BAC = beads after cleavage. B) Size exclusion chromatography 
chromatogram; red numbers on the bottom are the fractions collected by the ÄKTA Pure 
chromatography system (GE Healthcare). On the X-axis, the elution volume (in ml); on 
the Y-axis, the UV-light absorption at 280nm, expressed in mAU (milli Absorbance Units). 
C) SDS-PAGE of the fractions collected by the FPLC. They were not incubated with a 
reducing agent, and therefore in both lanes, there is a high concentration of dimer. This 








Figure C.10 Purification of GST. A) SDS-PAGE of the affinity purification on GSH 
beads and GSH elution of GST. The bacterial lysate was incubated with GSH Sepharose 
beads, leading to the immobilisation of GST onto them; the elution of GST (28.6kDa) was 
obtained with an excess of GSH solution. Abbreviations: SN = supernatant, FT = flow 
through, B = beads, E1,E2 = eluates, BAE = beads after elution. B) Size exclusion 
chromatography chromatogram; red numbers on the bottom are the fractions collected by 
the ÄKTA Pure chromatography system (GE Healthcare). On the X-axis, the elution 
volume (in ml); on the Y-axis, the UV-light absorption at 280nm, expressed in mAU (milli 
Absorbance Units). C) SDS-PAGE of the fractions collected by the FPLC. This gel confirms 
that GST is mostly in F5, F6 and F7. GST migrates as a double band in all fractions, most 
likely due to partial proteolytic degradation of the thrombin cleavage site near the C-








Figure C.11 Purification of GST-HH. A) SDS-PAGE of the affinity purification on GSH 
beads and elution of GST-HH. The bacterial lysate was incubated with GSH Sepharose 
beads, leading to the immobilisation of GST-HH onto them; the elution of GST-HH 
(45.3kDa) was obtained with an excess of GSH solution. Abbreviations: SN = supernatant, 
FT = flow through, B = beads, E1,E2 = eluates, BAE = beads after elution. B) Size exclusion 
chromatography chromatogram; red numbers on the bottom are the fractions collected by 
the ÄKTA Pure chromatography system (GE Healthcare). On the X-axis, the elution 
volume (in ml); on the Y-axis, the UV-light absorption at 280nm, expressed in mAU (milli 
Absorbance Units). C) SDS-PAGE of the fractions collected by the FPLC. This gel confirms 
that GST-HH is mostly between F6 and F8; in F9, some breakdowns are visible that were 
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D. Protein fusion attempts 
 
 
Figure D.1 Protein fusion attempts. Eleven SNARE fusions were expressed and 
purified over this project, of which only three were eventually characterised and used in 
further experiments. The SNARE fusion attempts that were not carried over are 
highlighted in yellow, and their outcome indicated, with the reasons for their rejection. 
The SNARE domains are represented with cylinders of different colours, while the linkers 
are shown as lines. VAMP2-S is represented here by a cylinder with the same length of 
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